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                                                                                          Introduction
1.  INTRODUCTION1
        Oral  route  of  drug  administration  is  oldest  and  safest  mode  of  drug
administration. It posses several advantages. It does not possess the sterility problem and
minimal risk of damage at the site of administration. It provides accurate dosing without
assistantship of administration. In conventional oral drug delivery system, there is little or
no control  over  release  of  drug,  and  effective  concentration at  the  target  site  can  be
achieved by administration of grossly excessive dosage form. This kind of dosing pattern
result in constantly changing, unpredictable and often sub or supra therapeutic plasma
concentration, leading to marked side effects in some cases. Moreover, the rate and extent
of absorption from conventional formulation may  vary greatly, depending on factor such
as  physiochemical  properties  of  drug,  presence  of  excipients,  various  physiological
factors such as presence or absence of food, pH of gastrointestinal tract, G.I. motility etc.
        The above problem can be minimized by oral controlled drug delivery.  In  oral
controlled drug delivery the amount of drug release is constantly predetermined and these
constant releases of drug provide a constant blood plasma level of drug for a therapeutic
response.  The  oral  controlled  drug  delivery  have  many  advantage  to  conventional
delivery-  it  decrease  the  fluctuation of  drug  plasma concentration,  it  reduce  toxicity,
provide a sustained effects, reduced the dosing frequency. Apart from other advantage it
reduces total amount of drug used, improve patient compliance and reduced patient care
time.
         
        The disadvantage of oral  controlled release product are longer  time to achieve
therapeutic blood concentration, possible increase variation in bioavailability after oral
administration, enhanced first pass effect, dose dumping, sustained concentration in oral
dose case, lack of doses flexibility and usually grater expense.
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        Hydrophilic polymers  are widely used in oral  controlled drug delivery due to
their flexibility to produce desirable drug release profile, cost effectiveness, and broad
regulatory  acceptance.  Among  the  hydrophilic  polymers,  HPMC
(hydroxyproylmethylcellulose) is the most widely used carrier for the preparation of oral
controlled drug delivery system due to its properties such as its ability to swell  upon
jellification once contact with water, and its very low toxicity and easy of manufacture,
the gel becomes a viscous layer acting as a protective barrier to both influx of water and
efflux of drug in the solution. On the other hand, hydrophobic polymer, such as EC can
be alternative to the swelling polymers by forming an inert matrix with no physiological
action  and  stable  at  different  pH  values  and  moisture  levels  when  a  tablet  with
hydrophobic matrix is placed in the dissolution medium, the drug at surface is released
quickly, with a possible burst effects, requiring its replacement drug from inner layers
that must diffuse through the pores until it reaches the surface.
        
        Physician can achieve several  desirable therapeutics  advantages  by prescribing
sustained release dosage form. Since, the frequency of drug administration is reduced,
patient’s compliances can be improved and the drug administration can be made more
convenient as well. The blood level oscillation characteristics of multiple dosing form of
conventional dosage form is reduced, because more even blood level is maintained in the
design of sustained release dosage form.  The total  amount of drug administered,  thus
maximum availability  with  a  minimum dose.  In  addition,  the  safety  margin  of  high
potency drug  can be  increased  and  the  incidence  of  both local  and  systemic  adverse
effects can be reduced in sensitive patients. Overall, increased administration of sustained
release dosage form gives increased reliability.
        Sustained  release  technology  is  relatively  new  field  and  as  a  consequence,
research in the field has been extremely fertile and has produced many discoveries. With
many drugs, the basic goal is to achieve a steady state blood level that is therapeutically
effective and non-toxic for an extended period of time.
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        The design of proper dosage form is an important element to accomplish this
goal. Sustained release, sustained action, prolonged action, controlled release, extended
action,  timed release  and depot  dosage  form are  term used  to  identify  drug  delivery
system  that  are  designed  to  achieve  prolonged  therapeutic  effect  by  continuously
releasing medication over an extended period of time after  administration of a single
dose. In the case of oral sustained released dosage form, an effect is for several hours
depending upon residence time of formulation in the GIT.
        Not all the drugs are the suitable candidates for the sustained release dosage
form. Ideal characteristic of the drug for the sustained release dosage form are;
 Drug should have a shorter half-life as drug with a longer half-life are inherently
long acting drugs.
 Drug  should  be  absorbed  from  large  portion  of  gastrointestinal  tract,  since
absorption must occur through the gut.
 Drug  should  be  having  a  good  solubility  profile  to  be  a  good  candidate  for
sustained release dosage form.
 Dose of the drug should not be too large, as a larger dose is to be incorporated
into sustained release dosage form.
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1.1 POTENTIAL ADVANTAGE OF SUSTAINED RELEASE DOSAGE FORM2: 
1) Avoid patient’s compliance problem due to reduced frequency of dosing.
2) Blood level oscillation characteristics of multiple dosing of conventional  dosage 
form are reduced because a more even blood level is maintained.
3) Employ a less total drug.
4) Minimize or eliminate local or systemic side effects.
5) Minimize drug accumulation with chronic dosing.
6) Obtained less potential of reduction in drug activity with chronic use.
7) Improved efficiency in treatment.
8) Cure or control condition more promptly.
9) Improved control of condition i.e. reduced fluctuation in drug level.
10)  Improved bioavailability of some drugs.
11)  Make a use of special effects, e.g. sustained release aspect for relief of    
       arthritis by dosing before bedtime.
12)  Economy.
13) Overall, administrations of sustained release form enable increased reliability of 
therapy.
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.
1.2 MATRIX SYSTEM3,4: 
      
  The  matrix  system  is  most  often  used  for  a  drug-controlled  release  from  a
pharmaceutical dosage form. Among the innumerable method used in controlled release
drug from pharmaceutical dosage form, the matrix system is the most frequently applied;
it is release system for delay and control of the release of the drug that is dissolved or
dispersed in a resistant supports to disintegration.
   To define matrix, it is necessary to know the characters that differentiate it from
other controlled release dosage forms. Hence the following must be considered:
 The chemical nature of support (generally, the support are formed by polymeric
net)
 The physical state of drug (dispersed under molecular or particulate form or both).
 The matrix shape and alteration in volume as a function of time.
 The route of administration (oral administration remains the most widely used but
other routes are adaptable).
 The release kinetic model.           
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1.3 THE CLASSIFICATION OF MATRIX SYSTEM:
       Mineral matrix:
        Drug retained in the support.
        Drug adsorbed on the support
        Lipidic matrix:
        Delivery by diffusion.
        Delivery by surface erosion
       Hydrophillic matrix:
       Unlimited swelling, delivery by diffusion.
       Limited swelling controlled delivery through swelling
       Inert matrix:
       Controlled delivery by diffusion
       Biodegradable matrix:
       Non-Lipidic.
1.4 ADVANTAGES OF MATRIX SYSTEM
         The interest awakened by matrix system in last few years is completely justified in
view of the major advantages. Among these, the following stand out. With proper control
of manufacturing process, reproducible release profiles are possible.
        There is no risk of “dumping” of a large part of dose, through the structure makes
the immediate release of a small amount of active principle unavoidable.
        Their capacity to incorporate active principle is large, which suits them to delivery
of large dosage          
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1.5 PRINCIPAL OF MODIFIED DRUG RELEASE 5,6: 
        Following either of the two principles can modify drug release.
1.5.1 Barrier principal 
        In this method the retardant material is imposed between the drug and elusion
medium. Drug release is by diffusion of the drug through the barrier and /or erosion of
the barrier or permeation of the barrier by moisture
                                                                                 .
Figure no.1.
Barrier mediated models of sustained release dosage form regimen.
 A. Drug diffusion through the barrier,
 B. permeation of barrier by elution media followed by drug dissolution,
 C. Erosion of barrier releasing drug,
 D. rupture of permeation of elutiomedia.
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1.5.2 Embedded matrix:
        In this drug is dispersed/embedded in a matrix of retardant material that may be
encapsulated in a particulate form or compressed into the tablet. Drug release occurs by
permeation of water leaching extraction of diffusion of drug from the matrix and erosion
of matrix material.  
Figure No. 2
Embedded matrix concept as a mechanism of controlled released in sustained
release
A. dosage form design network model a drug is insoluble in the retardant material. 
B  Drug  is  soluble  in  the  retardant  material.  Diffusion  profile  etc.  Characterize  drug
release from matrix system. 
1.6 SWELLABLE MATRIXS AS SYSTEM FOR ORAL DELIVERY 7:
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         Monolithic devices or matrices represent a substantial part of drug delivery
systems. Matrices containing swellable polymers are referred to as  
        Hydrogel matrices
        Swellable control release systems.
        Hydrophillic matrix tablet 
        Swellable matrices for oral administration are commonly manufactured as tablet
by  compression  of  hydrophilic  microparticulate  polymers.  Therefore,  the  most
appropriate  classification  for  these  systems  is  swellable  matrix  tablet.  They  are
constituted of a blend of drug and one or more hydrophilic polymers. 
        The  release  of  drug  from  swellable  matrix  tablet  is  based  on  glassy-rubbery
transition of polymer  as a  result  of water  penetration into the matrix.  The interaction
between  water,  polymer  and drug are  the primary factors  for  drug release.  However,
various formulation variables such as polymer grade, drug–polymer ratio, drug solubility
and drug and polymer particle size, can influence drug release rate to greater or lesser
degree. 
The central element of the mechanism of drug release in the gel layer (rubbery
polymer),  which is  formed around the matrix. The gel  layer  is  capable of preventing
matrix  disintegration  and  further  rapid  water  penetration.Water  penetration,  polymer
swelling, drug dissolution and diffusion and matrix erosion are phenomenon determining
gel layer thickness. Finally drug release is controlled by drug diffusion through the gel
layer and/or by erosion of the gel layer. 
1.7. MECHANISMS OF DRUG RELEASE FROM MATRIX SYSTEM 8,9
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        The release of drug from controlled devices is via dissolution of the matrix or
diffusion of drug through the matrix or a combination of the two mechanisms.
1.7.1. Dissolution controlled systems
        A drug with slow dissolution rate will demonstrate sustaining properties, since the
release of the drug will be limited by the rate of dissolution. In principle, it would seem
possible to prepare extended release products by decreasing the dissolution rate of drugs
that are highly water-soluble. This can be done by:
Preparing an appropriate salt or derivative
        Coating the drug with a slowly dissolving material – encapsulation dissolution
control  Incorporating the drug into  a  tablet  with a slowly dissolving carrier  – matrix
dissolution  control  (a  major  disadvantage  is  that  the  drug  release  rate  continuously
decreases with time).
        The dissolution process can be considered diffusion-layer-controlled, where the rate
of diffusion from the solid surface to the bulk solution through an unstirred liquid tablet
is the rate-determining step. The dissolution process at steady-state is described by the
Noyes-Whitney equation:
Dc/dt = kDA(Cs-C) = D/hA(Cs-C)
        dC - dissolution rate
        kd - the dissolution rate constant (equivalent to the diffusion coefficient
                                    Divided by the thickness of the diffusion layer D/h)
         D - Diffusion coefficient
        Cs - saturation solubility of the solid
         C - Concentration of solute in the bulk solution
        Equation 1 predicts that the rate of release can be constant only if the following
parameters  are  held  constant:  surface  area,  diffusion  coefficient  and  diffusion  layer
thickness and concentration difference. However, under normal conditions, it is unlikely
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that these parameters will remain constant, especially surface area, and this is the case for
combination diffusion and dissolution systems.
1.7.2. Diffusion controlled systems
        Diffusion systems are characterized by the release rate of a drug being dependent on
its  diffusion  through  an  inert  membrane  barrier,  which  is  usually  a  water-insoluble
polymer.  In  general,  two  types  or  subclasses  of  diffusion  systems  are  recognized:
reservoir devices and matrix devices. 
1.7.2.1. Reservoir devices
        In these formulations where tablet coating constitutes the main factor in controlling
drug release. Examples of materials used to control drug release include hardened gelatin,
methyl or ethyl cellulose, polyhydroxymethacrylate, methacrylate ester copolymers, and
various waxes. Ethyl cellulose and methacrylate ester copolymers are the most commonly
used systems in the pharmaceutical industry.
Figure3. Schematic representation of a matrix release system
1.7.3 Bioerodible and combination diffusion and dissolution system
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        Bioerodible devices constitute a group of system for which mathematical description
of release kinetics can be quite complex. Bioerodible matrix system consists of the drug
dispersed in an erodible matrix. 
                                                           
          
                    Drug dispersed in matrix 
                                  Time = 0
  
                  Drug dispersed in matrix 
                                  Time = t
Figure 4: Representation of a Bioerodible matrix system.
        Drug dispersed in the matrix before release at time = 0. At time = t release by drug
diffusion or matrix erosion has occurred.
        The mechanism of release from simple erodible slab, cylinders, and sphere has been
described .by Eq. A simple expression describing release from all three of these erodible
devices is 
M1/M = 1- (1-K0t/C0a)n
        Where n=3 for a sphere, n=2 for a cylinder and n=1 for a slab. The radius of a
sphere, or cylinder, or the half-height of a slab is represented by a. Mt is the mass of a
drug released  at  infinite  time.  As  a further  complication,  these  systems  can  combine
diffusion and dissolution of both matrix material and the drug. Not only can drug diffuse
out of the dosage form, but also the matrix itself undergoes a dissolution process. The 
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complexity  of  the system can  arise  from the  fact  that,  as  the  polymer  dissolves,  the
diffusional path-length for the drug changes. These usually result in a moving boundary
diffusion system. Zero order release can occur only if surface erosion occurs and surface
area  dose  not  change  with  time.  The  inherent  advantage  of  such  a  system  is  that
bioerodible property of the matrix dose not result in a ghost matrix.
 
The disadvantages of these matrix systems are that release kinetics is often hard to
control,  since  many  factors  affecting  to  both  the  drug  and  the  polymer  must  be
considered.  Another method for the preparation of bioerodible system is to attach the
drug directly to the polymer by a chemical bond. Generally, the drug is released from the
polymer by hydrolysis or enzymatic reaction. This makes control of the rate of release
somewhat easier. Another advantage of the system is the ability to achieve very high drug
loading, since the amount of drug placed in the system   is limited only by the available
sites on the carrier.
         A third type, which in this case utilizes a combination of dissolution and diffusion,
is that of a swelling controlled matrix. In this the drug is dissolved in the polymer, instead
of  an  insoluble  or  erodible  polymer.  This  allows  entrance  of  water  which  causes
dissolution of drug and diffusion out of the swollen matrix. 
            In these systems the release rate is highly dependent on polymer-swelling rate,
drug solubility,  and the amount of soluble fraction in the matrix. This system usually
minimizes burst effects, since polymer swelling must occur before drug release.
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1.8 ADVANTAGES OF HYDROPHILIC MATRIX TABLET 10,11,12 : 
1) With proper control of the manufacturing process, reproducible release profiles
are  possible.  The  variability  associated  with  them  is  slightly  less  than  that
characterizing coated release form.
2) Structure allows an immediate release of small amount of active principle there is
no risk of dose dumping.
3) Their  capacity  to  incorporate  active  principle  is  large,  which  suits  them  to
delivery of large doses. 
4) The manufacturing processes are notably simple. Tablet formulation can be done
via direct compression or by wet granulation techniques.
5) Large variety of nonexpensives gelling agents is approved for oral use by   the
Competent official organization.
6) The safety margin of high-potency drugs can be increased.
7) The drug release from hydrophilic matrices show a typical time dependent profile
i.e. decreased drug release with time because of increased diffusion path length. 
1.9 FACTORS INFLUENCING THE DRUG RELEASE FROM MATRIX:
 Choice of matrix material.
 Amount of drug incorporated in the matrix.
 Viscosity of the hydrophilic material in aqueous system at a fixed  
 Concentration. 
 Drug: matrix ratio.
 Tablet hardness, porosity, and density variation.
 Entrapped air in tablet.
 Tablet shape and size.
 Drug particle size.
 Solubility of drug in aqueous phase.
 Surfactants and other additives.
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1.10 TABLET MANUFACTURING METHODS 13 : 
        Tablets are manufactured by wet granulation, Dry granulation or direct compression
method.
1] Wet Granulation
 
         Wet granulation is the process in which a liquid is added to a powder in a vessel
equipped with any type of agitation that will produce agglomeration or granules. These
granules after drying are compressed to form tablet.
2] Dry Granulation
        In this technique, there is no use of liquids. The process involves the formation of
slugs. Then the slugs are screened or milled to produce granules. The granules formed are
then compressed to form tablet.
3) Direct compression
        The term direct  compression is  used to define the process by which tablet  is
compressed  directly  from powder  blends of  active ingredient  and  suitable excipients,
which will flow uniformly in the die cavity and forms a firm compact.
1.11  DRUG  PROPERTIES  RELEVENT  TO  CONTROLLED  RELEASE
FORMULATIONS 
        The design of controlled - release delivery systems is subject to several variables of
considerable importance. Among these are the route of drug delivery, the type of delivery
system, the disease being treated, the patient, the length of therapy and the properties of
the drug. Each of these variables are interrelated and this imposes certain constrains upon
choices for the route of delivery,  the design of the delivery system and the length of
therapy. Properties of drugs are very important for designing a sustained release dosage
form mainly physicochemical and biological properties of the drug are most important.
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1.11.1 Physicochemical properties:
 A) Aqueous solubility and pKa: 
         A drug to be absorbed it must be dissolved in the aqueous phase surrounding the
site of administration and then partition into the absorbing membrane. Two of the most
important physicochemical properties of a drug that influence its absorptive behavior are
its aqueous solubility and if it is a weak acid or base its pKa. These properties pay an
influential role in the performance of controlled release systems.
       The aqueous solubility of a drug influences  its  dissolution rate,  which in turn
establishes its  concentration solution and hence the driving force  for  diffusion across
membrane.
        Dissolution rate is related to aqueous solubility as shown by the Noyes-Whitney
equation that, under sink condition is:-
dc/dt = KDACS
        Where, dc/dt = Dissolution rate
                        KD = Dissolution rate constant.
                         A       = Total surface area of the drug particles. 
                         Cs      = Aqueous saturation solubility of the drug.
        The dissolution rate is constant only if surface area 'A' remain constant, but the
important point to note is that the initial rate is directly proportional to aqueous solubility
Cs. Therefore, aqueous solubility of a drug can be used as a first approximation of its
dissolution rate. Drugs with low aqueous solubility have low dissolution rates and usually
suffer oral bioavailability problems.
        
 Dept. of Pharmaceutics, PGPCPS&RI                                                              16
                                                                                          Introduction
       Aqueous solubility of weak acids and bases is governed by the pKa of the compound
and pH of the medium.
For weak acid,
St = So (1+ka/[H+]) = So(1+10 pH – pKa)…………...(1)
        Where, 
          St = Total solubility (both ionized and un-ionized forms) of the weak acid    
         So = Solubility of the un - ionized form
        Ka = Acid Dissociation constant
        H+ = hydrogen ion concentration of the medium. . 
        Equation (1) predicts that the total solubility, st of a weak acid with a given pKa can
be affected by the pH of the medium.
For a weak base,
St = So (1+[H+] / Ka = So (1+10 Pka – PH) ……………… (2)
       Where ,
        St = Total solubility (both conjugate acid and free base forms) of the weak base.
        So = Solubility of the free base form
        Ka= Acid dissociation constant of the conjugate acid. 
        So total solubility, St of a weak base whose conjugate acid has a given pKa, which
can be affected by the pH of the medium.
        In  general,  extremes  in  the aqueous  solubility  of  a  drug are  undesirable  for
formulation into controlled release product. A drug with very low solubility and a slow
dissolution  rate  will  exhibit  dissolution  limited  absorption  and  yield  an  inherently
sustained blood level. 
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        Formulation of such a drug into a controlled release system may not provide
considerable  benefits  over  conventional  dosage  forms.  Any system upon diffusion of
drug through a polymer as the rate - limiting step in release would be unsuitable for a
poorly soluble drug, since the driving force for diffusion is the concentration of drug in
the polymer or solution, and this concentration would be low.  For a drug with very high
solubility and a rapid dissolution rate, it is often quite difficult to decrease its dissolution
rate to slow its absorption. Preparing a slightly soluble form of a drug with normally high
solubility  is,  however,  one  possible  method  for  preparing  controlled  release  dosage
forms.
B) Partition Coefficient
        Between time that a drug is administered and the time is eliminated from the body, it
must diffuse through a variety of biological membranes that act primarily as lipid like
barriers. 
       A major  criteria  in evaluation of the ability of  a  drug to penetrate  these lipid
membranes is its apparent oil / water partition coefficient defined as
K = C0/CW
      Where,
Co  =  Equilibrium  concentration  of  all  forms  of  the  drug  e.g  ionized  and
unionized in  an organic phase at equilibrium.
           Cw =  Equilibrium concentration of all forms in aqueous phase.
        In general, drugs with extremely large values of ‘K’ are very oil soluble and will
partition into membrane quite readily. According to Haunch correlation, the logarithm of
the activity of  a  drug or  its  ability  to  be absorbed  and the  logarithm of  its  partition
coefficient having parabolic relationship. The explanation for this relationship is that the
activity of a drug is a function of its ability to cross membranes and interact with the
receptor.  The more effectively a drug crosses membranes, the greater its activity. The
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optimum partition coefficient  value  of  a  drug  in  which it  most  effectively permeates
membranes and thus shows the greatest activity.   
        The value of K at which optimum activity is observed is approximately 1000/1.
Drugs with a partition coefficient that is higher or lower than the optimum is, in general,
poorer candidates for formulation into controlled-release dosage forms.
C) Drug stability
        One important  factor  for  oral  dosage  forms is  the loss of  drug through acid
hydrolysis and/or metabolism in the GI tract. Since a drug in the solid state undergoes
degradation a much slower rate than a drug in suspension or solution. It  is possible to
improve significantly the relative bioavailability of a drug that is unstable in the stomach;
the most appropriate controlling unit would be one that releases its content only in the
intestine. The reverse in the case for those drugs that are unstable in the environment of
the intestine, the most appropriate controlling unit in this case would be one that releases
its  contents only in the stomach,  so,  drugs  with significant  stability problems in  any
particular area of the GI tract  are less suitable for formulation into controlled release
systems that deliver their content uniformity over the length of the GI tract. Controlled
drug delivery systems may provide benefits for highly unstable drugs because the drug
may be protected from enzymatic degradation by incorporation into a polymeric matrix.
D) Protein Binding
        There are some drugs which having tendency to bind with plasma proteins (e.g.
Albumin) and causes  retention  of  the drug  in  the vascular  space.  The main force  of
attraction responsible for binding is vanderwal forces, hydrogen bonding and electrostatic
forces. In general, charged compounds, because of electrostatic effects.
       If a drug binds with protein then the distribution of the drug into the extravascular
space is governed by the equilibrium process of dissociation of the drug from the protein.
The drug-protein complex can serve therefore as a reservoir in the vascular space for
controlled drug release to extravascular tissues, but only for those drugs that exhibit a
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high degree of binding. Thus, the protein binding characteristics of a drug can play a
significant role in its therapeutic effect, regardless of the type of dosage form. 
        Extensive binding to plasma proteins will be evidenced by a long half-life of
elimination for the  drug and such drugs generally does not required a controlled-release
dosage form, however, drugs that exhibit a high degree of binding to plasma protein also
might bind to biopolymers in the GI tract, which could have an influence on controlled-
drug delivery.
E) Molecular size and diffusivity:
       Drugs in many controlled-release systems must diffuse through a rate controlling
membranes or matrix. The ability of a drug to diffuse through membranes, it's so called
diffusivity  [diffusion  coefficient),  is  a  function  of  its  molecular  size  (or  molecular
weight). An important influence upon the value of the diffusivity. 'D', in polymers is the
molecular size for molecular weight) of the diffusing species. For most polymers, it is
possible to relate logD empirically to some function of molecular size as
Log D = -Sv log V + Kv   = - SM logM + Km
                     
                    Where,
V =  molecular Volume.
M =  molecular weight.
         SV,Sm,Kv, Km  =  constant
        The value of 'D' thus is related to the size and shape of the cavities as well as size
and  shape  of  drugs.  Generally,  values  of  the  diffusion  coefficient  for  intermediate
molecular, weight drugs, i.e.150 to 400, through flexible polymers range from 10-6 to 10-9
cm2 / sec, with values on the order of 108 being most common. A value of approximately
10-6 is typical for these drugs through water as the medium. For drugs with a molecular
weight greater than 500, the diffusion co-efficient in many polymers frequently are so
small  that  they  are  difficult  to  quantify,  i.e.,  less  than  10-12  cm2/sec.  Thus,  high
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molecular weight drugs and/or polymeric drugs should be expected to display very slow
release  kinetics  in  controlled  release  devices  using  diffusion  through  polymeric
membranes or matrices as the releasing mechanism.
1.11.2. Formulation variables
        The physicochemical characteristics of the drug, in particular its aqueous solubility,
should  be  considered  in  the  formulation  of  a  matrix  system.  Other  drug  properties
affecting system design include drug stability in the system and at the site of absorption,
pH-dependent solubility, particle size and specific surface area.
Drug particle size
       Effect of drug particle size on release is important in the case of moderately soluble
drugs. In the case of water-soluble aminophylline or propranolol HPMC-based tablet an
increase in drug particle size did not significantly alter the release rate of the drug. A
noticeable effect was seen only at a low drug: HPMC ratio and at a large drug particle
size (above 250µm), in this case, rapid dissolution of the water soluble drug would leave
a matrix with low tortuosity and high porosity.  Another study showed that for a given
effective surface area,  diclofenac particle size influenced the release rate from HPMC
tablet. The smallest particle size of drug dissolved more easily when dissolution medium
penetrated through the matrix resulting in a greater role for diffusion. The larger particle
size dissolved less readily and therefore was more prone to erosion at the matrix surface. 
Drug: polymer ratio
        For diclofenac tablet formulated with HPMC, an increase in polymer: drug ratio
reduced the release rate. This was because an increase in polymer concentration caused
an increase in the viscosity of the gel (by making it more resistant to drug diffusion and
erosion) as well as the formation of a gel layer with a longer diffusional path. Diffusional
release  of  the  water  soluble  drug  metoprolol  decreased  with  increasing  HPMC
incorporation. By varying the polymer level (Methocel® K4M 10-40%), Nellore et al.
(1998) achieved different metoprolol in vitro release profiles. 
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Polymer type
        Various grades of commercially available HPMC differ in the relative proportion of
the  hydroxypropyl  and  methoxyl  substitutions;  increasing  the  amount  of  hydrophilic
hydroxypropyl  groups  leads  to  a  faster  hydration:  Methocel®  K  >Methocel®  E  >
Methocel® F. Generally rapid hydrating Methocel® K grade is preferred, especially for
highly soluble drugs where a rapid rate of hydration is necessary. It is important to note
that  an  inadequate  polymer  hydration  rate  may lead  to  dose  dumping,  due  to  quick
penetration of gastric fluids into the tablet core (Dow Pharmaceutical Excipients, 1996).
In each grade, for a fixed polymer level, the viscosity of the selected polymer affects the
diffusional  and  mechanical  characteristics  of  the  matrix.  By  comparing  different
Methocel® K viscosity grades, the higher viscosity gel layers provided a more tortuous
and resistant barrier to diffusion, which resulted in slower release of the drug (metoprolol
HCl).  Sung  et  al.  (1996)  compared  different  viscosity  grades  of  HPMC (Methocel®
K100LV,  K4M,  K15M,  K100M).  The  fastest  release  of  adinazolam  mesilate  was
achieved for the K100LV formulation. The K4M formulation exhibited a slightly greater
drug release than K15M and K100M. Due to the lack of a significant difference in the
release  profiles between  K15M and  K100M, the authors  suggested a  limiting HPMC
viscosity  of  15000cP,  above which,  if  viscosity  increased,  the  release  rate  would  no
longer decrease. In the case of ethyl cellulose, the findings are completely different. The
lower viscosity grades of ethyl cellulose are more compressible than the higher viscosity
grades, resulting in harder tablet and slower release.
Fillers
        A study the effect of filler (57% of the tablet weight) on a metoprolol formulation at
20% Methocel® K4M level. They concluded that filler solubility had a limited effect on
release rate. The release profiles showed a decrease of about 5-7% after 6h, as the filler
was  changed  from  lactose  to  lactose  –  microcrystalline  cellulose  then  to  dicalcium
phosphate dihydrate -microcrystalline cellulose. Addition of soluble fillers enhanced the
dissolution of soluble drugs by decreasing the tortuosity of the diffusion path of the drug,
while insoluble fillers like dicalcium phosphate dihydrate got entrapped in the matrix.
Also, it was assumed that the presence of swelling insoluble filler like microcrystalline
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cellulose changed the release profile to a small extent due to a change in swelling at the
tablet surface.  Changing the filler from 100% dicalcium phosphate dihydrate to 100%
lactose resulted in an increase in metoprolol release from Methocel® K100LV tablet at 4,
6 and 12h this was explained by dissolution of lactose and the consequent reduction in
the  tortuosity  and  or  gel  strength  of  the  polymer.  Similar  dissolution  profiles  were
obtained for filler concentration up to 48%. No dose dumping due to stress cracks (Dow
Pharmaceutical Excipients, 1996) during gelling were observed in the case of insoluble
fillers.
Polymeric excipients
        A study reported that non-ionic polymers did not alter drug release significantly
from HPMC matrices; however, ionic polymers were capable of retarding the release of
oppositely charged molecules. They studied the effect of polymeric additives (non-ionic
polyethylene glycol 6000 or ethyl cellulose, cationic diethylaminoethyl dextran, anionic
sodium carboxymethyl cellulose Na-CMC) on drug release (chlorpheniramine maleate,
sodium  salicylate  and  potassiumfenoxymethylpenicillin)  from  HPMC  matrix  (85%).
Non-ionic polymers (15% of tablet weight) did not significantly alter the release rates.
Na-CMC (50% replacement of HPMC) reduced the chlorpheniramine maleate release in
pH  7  buffer  (near  zero  order  release),  but  not  in  an  acidic  medium.  There  was  a
complexation of the drug with the anionic polymer; which was not possible below pH 3,
when Na-CMC was in its unionized insoluble form. As a result of the complexation, the
gel erosion became the prominent release mechanism instead of diffusion. No interaction
occurred  between  sodium salicylate  and  Na-CMC (both  anionic).  In  the  presence  of
diethylaminoethyl dextran, sodium salicylate release was slower at pH 7, but not altered
at pH 1 (when the drug was present in its unionized form). Overall, the effect of ionic
polymers incorporated into HPMC matrices on the release of oppositely charged drugs
was  small.  The  drug-polymer  ionic  complexation  approach  in  designing  oral  dosage
formulation  for  controlled  release  of  buspirone.  Anionic  exchange  polymers  sodium
carboxymethyl  cellulose  and  methacrylic  acid  /ethylacrylate  copolymer  were
recommended  based  on  the  complexation  affinity  and  dispersability  in  the  aqueous
environment  of  the  gastrointestinal  tract.  The  weight  ratio  of  buspirone  to  anionic
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exchange  polymer  varied  between  4:1  and  1:6,  preferably  between  2:1  and  1:4.  In
addition to facilitating the controlled release of buspirone, the formulations increased the
bioavailability and reduced the inter-individual variability. Therefore, the buspirone-ion
exchange polymer HPMC tablet permitted enhanced targeting of therapeutic amounts and
effects of the drug. The addition of anionic polymers (Eudragit® S, Eudragit® L 100-55,
and Na-CMC) on the release of weakly basic propranolol  hydrochloride from HPMC
matrices.  The  interaction  between  propranolol  hydrochloride  and  anionic  polymers
influenced the drug release.  The HPMC: anionic polymer ratio also affected the drug
release.  The  matrix  containing  HPMC:  Eudragit®  L  100-55  (1:1)  produced  pH-
independent extended release tablet. An optimization procedure to determine the HPMC:
e-carrageenan ratio (34:30) required for a pH-independent release of chlorpheniramine
maleate. e-Carrageenan was added to overcome the increase in diffusion path length and
decrease in the release rate associated with HPMC systems. e-carrageenan was subjected
to erosion, which was higher at acidic pH.
1.11.3 PROCESS VARIABLES
A) Compression force: 
        The compression force had a significant effect on tablet hardness; its effect on drug
release  from  HPMC  tablet  was  minimal.  It  could  be  assumed  that  the  variation  in
compression force should be closely related to a change in the porosity of the tablet.
However, as the porosity of the hydrated matrix is independent of the initial porosity, the
compression  force  seems  to  have  little  influence  on  drug  release.  The  changes  in
compression force or crushing strength had minimal effect on drug release from HPMC
matrix  tablet  once  critical  hardness  was  reached.  Increased  dissolution  rates  were
observed when the tablets were found to be extremely soft, and this phenomenon was
attributed to a lack of powder compaction, as tablet hardness was only 3 kp.
B) Tablet shape:
        The size and shape of the tablet for the matrix system undergoing diffusion and
erosion  might  impact  the  drug  dissolution  rate.  Modification  of  the  surface  area  for
metoprolol  tartrate  tablet  formulated  with  Methocel®  K100LV  from  the  standard
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concave shape (0.568 sq. in.) to caplet shape (0.747 sq. in.) showed an approximately 20-
30% increase in dissolution at each time point. Based upon these results, the researchers
concluded  that  for  maximum  uniformity  of  extended  release  characteristics,  tablet
matrices should be manufactured to be as spherical as possible, in order to produce the
minimum release rate, with regard to tablet shape. Varying the aspect ratio (radius/height)
of the HPMC tablet is a very easy and effective tool to modify the release rate of the
matrix system.
                  
                     Release rate for tablet with the same volume was higher for flat shape (ratio
= 20) than regular cylinders (ratio 2) and almost rod-shaped cylinders (ratio 0.2). The
results were attributed to difference in tablet surface area.  A mathematical  model was
proposed that could employ in order to calculate the optimal aspect ratio and size of a
cylindrical  tablet  required  to  achieve  a  specific  release  profile.  The  model  takes  into
account Fickian diffusion of water in and drug out of the tablet and swelling; it does not
take into account dissolution and it cannot be applied for water insoluble drugs, which are
released by dissolution process. The mathematical model proposed above was then used
to  predict  the  dissolution  rates  of  propranolol  hydrochloride  and  chlorpheniramine
maleate (water soluble drugs).
C) Tablet size:
        For tablet having the same aspect ratio and drug concentration, the tablet size had a
very strong influence on the release rate; within 24 hours, 99.8% was released from the
small  tablet,  83.1% from  the  medium size  and  50.9% from  the  large  tablet.  It  was
hypothesized  that  the  smaller  tablet  released  drug  more  rapidly  due  to  an  increased
surface area per volume. Additionally, it was concluded that larger diffusion pathways
existed in the larger tablet leading to a decrease in drug release.
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1.11.4 BIOLOGICAL PROPERTIES
I) Absorption:
        The rate, extent and uniformity of absorption of a drug are important factors when
considering it's formulation into a controlled - release system. Since the rate limiting step
in drug delivery from a controlled-release system is its release from a dosage form, rather
than absorption, a rapid rate of absorption of drug relative to its release is essential if the
'system is to be successful.  In  case of controlled release dosage form Kr<<< Ka this
becomes most critical in the case of oral administration. Assuming that the transit time of
a drug through the absorption half-life should be to 4 hrs. This corresponds to a minimum
absorption rate constant Ka of 0.17 to 0.23 hr necessary for about 80 to 95 % absorption
over a 9 to 12 hr transit time. For a drug with a very rapid rate of absorption, (i.e. Ka
>>0.23 hr-1), the above discussion implies that a first order release rate constant Kr <
0.17  hr-1  is  likely  to  result  in  unacceptable  poor  bioavailability  in  many  patients.
Therefore,  slowly absorbed drugs will be difficult to formulate into controlled release
systems where the criteria that Kr <<< Ka must be met.
II) Distribution:
        The distribution of a drug into vascular and extravascular spaces in the body is an
important  factor  in  its  overall  elimination  kinetics.  Two  parameters  that  are  used  to
describe the distribution characteristics of a drug are its apparent volume of distribution
and the ratio of drug concentration in the tissue is that in plasma at the steady state called
T/P ratio. The magnitude of the apparent volume of distribution can be used as a guide
for additional studies and as a predictor for a drug dosing regimen and hence there is a
need to employ a controlled-system.
III) Metabolism:
        Drugs that are significantly metabolized before absorption, either in the lumen or:
tissue of the intestine can show decreased bioavailability from slower-releasing dosage
forms. Most intestinal wall enzyme systems are saturable. As the drug is released at a
slower rate to these regions, less total drug is presented to the enzymatic process during a
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specific period allowing more complete conversion of drug to its metabolite. Formulation
of these enzymatically susceptible compounds as prodrug is another viable solution.
IV) Biological Half Life:
        The usual goal of an oral sustained release product is to maintain therapeutic blood
levels over an extended period. To this, drug must enter the circulation at approximately
the same rate at which it is eliminated. The elimination rate is quantitatively described by
the half-life. Each drug has its own characteristics elimination rate, which is the sum of
all elimination processes including metabolism, urinary excretion and all other processes
that  permanently remove drug from blood stream. Therapeutic  compounds with  short
half-life are excellent candidates for sustained-release preparations, since this can reduce
dosage frequency.  However, this is limited, in that drugs with very short biological half
life as it may require excessively large amounts of drug in each dosage unit to maintain
sustained effect, forcing the dosage form itself to become limitingly large.
        In general, drugs with half-life shorter than two hrs are poor candidates for sustained
release preparations. Drugs with long half-life, more than 8 hrs, are also generally does
not be used in sustaining forms, since their effect is already sustained.
  
V) Side Effects and Safety Considerations:
         There are very few drugs whose specific therapeutic concentrations are known.
Instead, a therapeutic concentration range is listed, with increasing toxic effects expected
above this range and a fall off in desired therapeutic response observed below the range.
        The most widely used measure of the margin of safety of a drug is its therapeutic
index, (Tl).
TI =   LD50/ ED50
       Where,
         LD50 = median lethal dose
         ED50 = median effective dose
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        For very potent drugs, whose therapeutic concentration range is narrow, the value TI
is small. In general, larger the value of TI, Usually are poor candidates for formulation
into controlled-release product. A drug is considered to be relatively safe if its TI value
exceeds 10.
VI) Dose Size:
        Since a controlled-release system is designed to alleviate repetitive dosing, it is
naturally contain greater amount of drug that a corresponding conventional dosage form.
For lose drugs requiring large conventional doses, the volume of sustained dose may be
so large so to be impractical or unacceptable, depending on the route of administration.
The same may be true for drugs that require a large release rate from the controlled-
release system, e.g., drugs with shorter half-life. For oral route, the volume of the product
is limited by patient acceptance.
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 AIM AND OBJECTIVE
The aim of this study is to formulate and evaluate the extended release
tablets of Trimetazidine hydrochloride.
 
2.1 REASONS FOR USING  TRIMETAZIDINE HYDROCHLORIDE IN
EXTENDED RELEASE FORMULATION:-
 Trimetazidine hydrochloride is prescribed to Patients to prevent the pain 
of chest due to lack of oxygen to the muscles of heart.
 Trimetazidine hydrochloride in the Extended release  is used to improve the
bioavailablity
 Trimetazidine hydrochloride in the Extended release  is used to improve the
Patients non compliance.
  2.2 REASONS FOR SELECTION OF DOSAGE FORM
 The goal of any drug delivery system is to provide a therapeutic amount of
drug to the proper site in the body to promptly achieve and maintain the
defined drug concentration.
  In pharmaceutical practice, drug administration to patient exists in several
approaches, one of which is conventional, i.e. drug is given several times a
day, to produce desired therapeutic effect.
  Due to frequent dosing, fluctuation in the drug blood level occurs; hence
maintenance  of  defined  drug level  can  be above or  below the  minimum
therapeutic level. The conventional tablet provides only a single transient
release of drug.
 Hence  the  above  potential  problem  can  be  minimized  or  reduced  by
formulating the drug in  release  control  matrix  i.e.  sustain release system
.This  system  minimizes  or  eliminates  side  effects,  provide  patient
compliance, economically and promptly achieves and maintains the desired
effect.
Hence due to above properties, it may be more efficient to deliver
the drug at a sustained  manner, at a reduced input rate compared with oral
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conventional  dose  occurring  from  a  Extended  release  dosage  form
Trimetazidine hydrochloride is available in market, presently.
   2.3 The main objective of present study:-
 The present study  is to investigate the possibility of developing extended
release dosage form for the drug Trimetazidine hydrochloride by using
polymers HPMCK15CR & Ethyl cellulose and Metalose in different ratios
as matrix
  It can be achieved by planning for trails until the desired release pattern is
obtained. The aim is to evaluate the release profile of drug from fabricated
extended release tablets.
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3. PLAN OF WORK
I. Literature survey
II. Preformulation studies -
• Drug excipients compatibility study by IR spectra
• Determnation of  λ max
• Bulk density
• Tapped density
• Carr’s Index (Compressibility Index) 
•  Hausner’s Ratio
III. Preparation of Matrix tablets by using matrix forming polymers
• Method
 By Wet granulation method
  IV. Evaluation of Matrix tablets by
•  Thickness
•  Hardness
•  Weight variation
•  Friability
•  In-vitro drug release study
•  Swelling Index
  V. Stability study.
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4. REVIEW OF LITERATURE
Review of literature showed that  the matrix formulation for oral  administration of
many drugs are tried using various polymers and other release retardants
.
P. D. NAKHAT  et.al.14 “Developing sustained release matrix  tablets of diclofenac
sodium by using different drug: polymer ratios. Xanthan gum w as used as matrix former, and
microcrystalline cellulose as diluent. All the lubricated formulations were compressed using 8
mm flat faced punches. Hence, Xanthan gum can be used as an effective matrix former, to
extend the release of diclofenac sodium”.
 Chowdary KPR  et al.15 “Olibanum and its resin and carbohydrate fractions were
evaluated as rate controlling matrix materials in tablets for controlled release of diclofenac.
Diclofenac  matrix  tablets  were  formulated  employing  olibanum  and  its  resin  and
carbohydrate fractions in different concentrations and the tablets were evaluated for various
tablet characters including drug release kinetics and mechanism. Diclofenac matrix tablets
formulated  employing  olibanum  and  its  resin  component  provided  slow  and  controlled
release of  diclofenac over  more than  24 h.  Drug release from the matrix  tablets  was by
Fickian diffusion and followed first order kinetics”.
 S  C  Basak et  al.16 “Monolithic  matrix  tablets  of  ambroxol  hydrochloride  were
formulated as sustained release tablets employing hydroxypropyl methylcellulose polymer,
and  the  sustained  release  behaviour  of  the  fabricated  tablets  was  investigated.  Sustained
release  matrix  tablets  containing  75  mg  ambroxol  hydrochloride  were  developed  using
different drug polymer ratios of hydroxypropyl methylcellulose”.
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 J.P.G. Brakenhoff et al. 17 “The effect of age and renal function on the pharmacokinetic
profile of a modified release tablet of trimetazidine (TMZ MR 35 mg) administered twice
daily.
             Methods- Study 1: Twelve healthy elderly subjects (CLcreat 72±8 ml/min, 72±4 years
mean±SD) and eight young volunteers (CLcreat 134±18 ml/min, 25±8 years) received TMZ
MR 35 mg b.i.d. (eight doses). Study 2: eight patients with severe renal failure (CLcreat. 17±5
ml/min, 54±10 years), five patients with moderate renal failure (CLcreat. 39±6 ml/min, 54±15
years) and eight volunteers (CLcreat. 104±17 ml/min, 53±9 years) received TMZ MR 35 mg
b.i.d.  (patients:  ten  doses,  volunteers:  eight  doses).  Serial  blood  and  urine  samples  were
obtained following administration of  the last  dose in  each study.  TMZ plasma and urine
concentrations were determined by gas chromatography (NPD-detector). The resulting data
were analysed using standard non-compartmental pharmacokinetic methods”.
 Basak  SC  et  al.18 “Monolithic  matrix  tablets  of  ambroxol  hydrochloride  were
formulated as sustained release tablets employing hydroxypropyl methylcellulose polymer,
and the sustained release behaviour of the fabricated tablets was investigated. The results of
dissolution studies indicated that a decrease in release kinetics of the drug was observed on
increasing polymer ratio. The mechanism of drug release from the optimized formulation was
diffusion coupled with erosion (anomalous)”.
 R.K.Khar  et al.19 “Compressed tablets were prepared from theophylline and guar
gum. Effect  of  the viscosity grade of  the polymer and polymer content  in the tablets on
release pattern of theophylline was examined in vitro. Release rate was retarded with increase
in polymer content as well as the viscosity grade of polymer”.
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M. Marzilli  et al20. “The efficacy of trimetazidine as an antianginal drug has been
assessed  in  randomized,  placebo-controlled  studies,  both  as  ‘solo’  treatment  and  in
combination with betablockers and calcium channel blockers.In patients with chronic angina,
trimetazidine increases work capacity and delays the appearance of symptoms and ECG 
             changes during exercise.  The benefits observed after acute administration are
maintained in chronic treatment with trimetazidine, which is well tolerated by patients”.
 Balasubramaniam et  al21. “Matrix tablets of cisapride and atenolol were prepared
with varying proportions of hydroxypropylmethylcellulose of different viscosity grades viz;
E15,E4M, K4M, And K15M, alone and combinations by wet  granulation technique.  The
study also indicated that the amount of drug released decreased with an increase the polymer
concentration.  The  combination  of  the  different  viscosity  grades  did  not  provide  any
additional advantage”.
P D Nakhat et al.22 “In  the  present  investigation,  an  attempt  has  been  made  to
increase  therapeutic  efficacy,  reduce  frequency  of  administration,  and  improve  patient
compliance, by developing sustained release matrix tablets of diclofenac sodium. Sustained
release matrix tablets of diclofenac sodium, were developed by using different drug: polymer
ratios, such as F1 (1:0.12), F2 (1:0.16), F3 (1:0.20), F4 (1:0.24) and F5 (1:0.28). Xanthan
gum was used as matrix former, and microcrystalline cellulose as diluent. All the lubricated
formulations were compressed using 8 mm flat faced punches”. 
Haider S.S.  et al.23 “ Sustained release preparetations of metoclopramide HCl were
prepared using carnauba wax and stearic acid as matrix formers. Granules were prepared by
melt dispersion method while tablets were made by direct compression”. 
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The fastest  release rate  was observed at  pH 4.5 and the slowest  at  pH 1.2 which
coincides with the drug's solubility behavior. The drug release kinetics followed the Higuchi's
square root model in all cases
.
 Rathnanand  M.  et  al.24 studied  to  develop  sustained  release  matrix  tablets  of
Terbutaline Sulphate.The tablets were prepared by wet granulation method using isopropyl
alcohol  with  stearyl  alcohol  as  granulating  agent.  Hydrophilic  matrix  materials  like
hydroxypropylmethylcellulose(HPMC), hydrophobic polymer such as Eudragit RLPO where
used  in  the  study.  All  the  formulations  exhibited  Higuchi-dominated  drug  release.  The
mechanism of drug release was found to be diffusion controlled.
  
Thapa P. et al.25 studied the effect of different viscosity grade of HPMC and drug
solubility  on  in-vitro  release  from matrix  tablets.  In  addition  to  release  mechanism,  the
release rate and mean dissolution time for propranolol HCl, salicylic acid and furosemide was
compared  using  Krosmeyer-peppas  equation.  The  release  mechanism  was  found  to  be
predominately diffusion controlled, anomalous, and case II transport type. 
Nashiru Billa  et al.26 studied processing variables at the laboratory and pilot scales
that can affect hydration rates of xanthan gum matrices containing diclofenac sodium and the
rate of drug release.  Drug release was linear from xanthan gum matrices prepared at  the
laboratory scale and pilot scales; however, release was faster from the pilot scales. 
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M. Helena  Amaral  et  al.27 “effect  of  the  concentration  of  hydrophilic  (hydroxyl
propyl methyl cellulose [HPMC] and hydrophobic (hydrogenated castor oil [HCO] products,
fillers  (lactose and dibasic calcium phosphate),  and buffers  (sodium bicarbonate,  calcium
carbonate, and sodium citrate) on naproxen release rate was studied.
 
 Robert O.  Williams III  et  al.28 studied a reverse-phase  high-performance liquid
chromatographic  (HPLC)  method  for  recovery  of  the  lipophilic  drug,  alprazolam,  from
matrix tablets containing the hydrophilic polymer hydroxylpropylmethylcellulose (HPMC)
was developed. The recovery method reported here in was shown to be the most efficient to
achieve complete recovery of alprazolam from powder blends and tablets containing a variety
of excipients and different grades of HPMC.
 Sandip B. Tiwari  et  al.29 studied the effect  of  concentration of  hydrophilic  (hy-
droxypropyl methylcellulose [HPMC]) and hydrophobic polymers (hydrogenated castor oil
[HCO],  ethylcellulose)  on  the  release  rate  of  tramadol  were  studied.  Hydrophilic  matrix
tablets were prepared by wet granulation technique, while hydrophobic (wax) matrix tablets
were  prepared  by  melt  granulation  technique.  Hydro-phobic  matrix  tablets  resulted  in
sustained in vitro drug release (>20 hours) as compared with hydrophilic ma-trix tablets (<14
hours). The presence of ethylcellulose in either of the matrix systems prolonged the release
rate of the drug.
 K. Raghuram Reddy et al.30 studied to develop once-daily sustained-release matrix
tablets of nicorandil, a novel potassium channel opener used in cardiovascular diseases. The
tablets were prepared by the wet granulation method. Ethanolic solutions of ethylcellulose
(EC), Eudragit RL-100, Eudragit RS-100, and polyvinylpyrrolidone were used as granulating
agents along with hydrophilic matrix materials like hydroxypropyl methylcellulose (HPMC),
sodium  carboxymethylcellulose,  and  sodium  alginate.  The  results  of  dissolution  stud-ies
indicated that formulation (drug-to-HPMC, 1:4; ethanol as granulating agent) could extend
the drug release up to 24 hours. 
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 Svetlana Ibric et al.31   studied  to model the effects of the concentration of Eudragit
L 100 and compression pressure as the most important process and formulation variables on
the in vitro release pro-file of aspirin from matrix tablets formulated with Eudragit L 100 as
matrix substance and to optimize the formulation by artificial neural network.
 Srisagul Sungthongjeen et al.32 “Effect of 2 formula-tion variables, the pectin type
(with different degrees of es-terification [DEs] and the amount of calcium, on drug re-lease
from pectin-based matrix  tablets.  The results  were more pronounced in phosphate buffer,
where the phosphate ions induced the pre-cipitation of calcium phosphate.  In  conclusion,
both pectin type and added calcium affect the drug release from the pec-tin-based matrix
tablets”.
 Meena Rani  et al.33 studied to Prepared and comparative evaluation of fabricated
matrix (FM), osmotic matrix (OM), and osmotic pump (OP) tablets for controlled delivery of
diclofenac sodium (DS). It was concluded that the osmotic matrix and osmotic pump tablets
could provide more prolonged,  controlled,  and gastrointestinal  environmental  independent
DS release that may result in an improved therapeutic efficacy and patient compliance.
 Saleh M. Al-Saidan  et al.34 “Develop guar gum matrix tablets for oral controlled
release of water-soluble diltiazem hydrochloride. Matrix tablets of diltiazem hydrochloride,
using  various  viscosity  grades  of  guar  gum  in  2  proportions,  were  prepared  by  wet
granulation method and subjected to in vitro drug release studies. Based on the results of in
vitro and in vivo studies it was concluded that that guar gum matrix tablets provided oral
controlled release of water-soluble diltiazem hydrochloride”.
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Mohammad Reza Siahi  et al.35  “Design oral controlled delivery systems for the
water-soluble drug, verapamil hydrochloride,  using natural  and semisynthetic polymers as
carriers in the forms of 1- and 3-layer matrix tablets. Verapamil hydrochloride 1-layer matrix
tablets  containing  hydroxylpropylmethylcellulose,  tragacanth,  and  acacia  either  alone  or
mixed were prepared by direct compression technique. 
The results also showed that the location of the polymers in the 3-layer tablets has a
pronounced  effect  on  the  drug  release.  Kinetic  analysis  of  drug  release  from  matrices
exhibiting  sustained  release  indicated  that  release  was  predominantly  attributable  to  the
contribution made by Fickian diffusion, while the erosion/relaxation mechanisms had a minor
role in the release”.
 Bhupinder Singh et al.36  Design oral controlled release mucoadhesive compressed
hydrophilic matrices of atenolol and to optimize the drug release profile and bioadhesion
using response surface methodology. A central composite design for 2 factors at 3 levels each
was  employed  to  systematically  optimize  drug  release  profile  and  bioadhesive  strength.
Carbopol 934P and sodium carboxy methyl cellulose were taken as the independent variables.
Besides unraveling the effect of the 2 factors on the various response variables, the study
helped in finding the optimum formulation with excellent bioadhesive strength and controlled
release.
 Jaleh Varshosaz et al.37  developed matrix sustained release tablets of highly water-
soluble  tramadol  HCl  using  natural  gums  (xanthan  [X  gum]  and  guar  [G  gum])  as
costeffective, nontoxic, easily available, and suitable hydrophilic matrix systems compared
with the  extensively investigated  hydrophilic  matrices  (ie,  hydroxypropyl  methylcellulose
[HPMC]/carboxymethyl  cellulose  [CMC]  with  respect  to  in  vitro  drug  release  rate)  and
hydration rate of the polymers. Tablets with only X had the highest mean dissolution time
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(MDT), the least dissolution efficiency (DE8%), and released the drug following a zero-order
model via swelling, diffusion, and erosion mechanisms. Guar gum alone could not efficiently
control the drug release, while X and all combinations of natural gums with HPMC could
retard tramadol HCl release. However, according to the similarity factor ( f2), pure HPMC
and H8G2 were the most similar formulations to Topalgic-LP as the reference standard.
 Carla Martins Lopes et al.38 was studied to produce a quick/slow biphasic delivery
system for ibuprofen. A dual component tablet made of a sustained release tableted core and
an immediate release tableted coat was prepared by direct compression. Both the core and the
coat contained a model drug (ibuprofen). The sustained release effect was achieved with a
polymer  (hydroxyl  propyl  methylcellulose  [HPMC]  or  ethyl  cellulose)  to  modulate  the
release of the drug. The in vitro drug release profile from these tablets showed the desired
biphasic  release  behavior:  the  ibuprofen  contained  in  the  fast  releasing  component  was
dissolved within 2 minutes, whereas the drug in the core tablet was released at different times
(≈16 or 924 hours), depending on the composition of the matrix tablet. Based on the release
kinetic  parameters  calculated,  it  can  be  concluded  that  the  HPMC core  was  suitable  for
providing a constant and controlled release (zero order) for a long period of time.
 Amelia Avachat  et al.39 Develop and characterize an oral  controlled release drug
delivery system for concomitant administration of diclofenac sodium (DS) and chondroitin
sulfate (CS).  A hydrophilic matrix-based tablet  using different  concentrations of hydroxyl
propyl methylcellulose (HPMC) was developed using wet granulation technique to contain
100  mg  of  DS  and  400  mg  of  CS.  In  conclusion,  the  in  vitro  release  profile  and  the
mathematical models indicate that release of CS and DS can be effectively controlled from a
single tablet using HPMC matrix system. 
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Hamdy  Abdelkader  et  al.40 was  investigating  different  types  and  levels  of
hydrophilic matrixing agents, including methylcellulose (MC), sodium alginate (Alg),  and
sodium carboxy methylcellulose (CMC), in an attempt to formulate controlled-release matrix
tablets containing 25 mg baclofen. The tablets were prepared by wet granulation. Prior to
compression, the prepared granules were evaluated for flow and compression characteristics.
In  vitro,  newly  formulated  controlled-release  tablets  were  compared  with  standard
commercial  tablets  (Lioresal  and  baclofen).  The  prepared  matrix  tablets  showed  good
mechanical  properties  (hardness  and  friability).  MC-  and  Alg-based  tablet  formulations
showed high release-retarding efficiency, and good reproducibility and stability of the drug
release profiles when stored for 6 months in ambient room conditions, suggesting that MC
and Alg are good candidates for preparing modified release baclofen tablet formulations
 Atul Kuksal et al.41 was studied to prepare and characterize extended-release matrix
tablets of zidovudine using hydrophilic Eudragit RLPO and RSPO alone or their combination
with  hydrophobic  ethyl  cellulose.  Release  kinetics  was  evaluated  by using United  States
Pharmacopeia (USP)-22 type I dissolution apparatus. The in-vitro drug release study revealed
that either Eudragit preparation was able to sustain the drug release only for 6 hours (94.3% ±
4.5% release).  Combining Eudragit  with ethyl  cellulose sustained the drug release for 12
hours (88.1% ± 4.1% release). Fitting the in vitro drug release data to Korsmeyer equation
indicated that diffusion along with erosion could be the mechanism of drug release. In vivo
investigation in rabbits showed sustained-release pharmacokinetic profile of zidovudine from
the  matrix  tablets  formulated  using  combination  of  Eudragits  and  ethylcellulose.  In
conclusion,  the  results  suggest  that  the developed sustained-release  tablets  of  zidovudine
could  perform therapeutically  better  than  conventional  dosage  forms,  leading  to  improve
efficacy and better patient compliance.
 
                 Punna R. R. et al.42 ,Oral controlled release matrix tablets of zidovudine were
prepared  using  different  proportions  and  different  viscosity  grades  of  hydroxypropyl
methylcellulose. The effect of various formulation factors like polymer proportion, polymer
viscosity and compression force on the in vitro release of drug were studied. In vitro release
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studies  revealed  that  the  release  rate  decreased  with  increase  in  polymer  proportion and
viscosity grade. Mathematical analysis of the release kinetics indicated that the nature of drug
release from the matrix tablets followed non-Fickian or anomalous release. The developed
controlled release matrix tablets of zidovudine, with good initial release (17—25% in first
hour)  and  which  extend  the  release  upto  16—20 h,  can  overcome the  disadvantages  of
conventional tablets of zidovudine.
 Nokheldchi A. et al.43, The effects of various polymers on the release of Diclofenac
Sodium from matrics. In vitro release profile of Diclofenac Sodium from ethyl cellulose and
HPMC K4M  matrices  showed  that  decreasing  the  concentration  of  Ethyl  Cellulose  and
increase in the concentration of HPMC K4M resulted in an increase in the release rate of
Diclofenac Sodium.  
 B.S. Nath et.al.44,The using a combined hydrophobic and hydrophilic matrix on the
release  of   Theophylline.  Combination  of  aliphatic  alcohol  (cetyl  alcohol  (cetyl  alcohol)
partially hydrated Methylcellulose was investigated as a sustain release matrix. The in-vitro
release data showed that the total matrix component gave extended release of Theophylline
for  more than 8 hours  and the drug release from the matrix  indicated that  the drug was
released by diffusion obeying first order rate kinetics.
 
 Chowdary  K.P.R.  et  al.45 ,  Sustained  release  of  Nifedipine  tablets  by  using
soliddispersion in HPMC with HPC and reported that its gave slow, controlled and complete
release spread over a period of 12 hours. Drug release from these tablets followed zero order
kinetics and release was by diffusion controlled.
 M.  Helena  Amaral et  al.46 ,  The  effect  of  the  concentration  of  hydrophilic
(hydroxypropyl methylcellulose [HPMC]) and hydrophobic (hydrogenated castor oil [HCO])
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products, fillers (lactose and dibasic calcium phosphate), and buffers (sodium bicarbonate,
calcium carbonate, and sodium citrate) on naproxen release rate was studied. Matrix tablets
were prepared by double compression, and In vitro dissolution tests were performed. The
dissolution results showed that an increased amount of HPMC or hydrogenated castor oil
resulted in reduced drug release.
 Efentakis M.,  et al.47 ,The effect of excipients on swelling and drug release from
compressed matrices. The result showed that mechanisms are affected by the composition of
matrix.
 Efentakis.  et al.48 ,The influence of surfactant on drug release from a hydrophobic
matrix. Hydrophobic materials were prepared using Eudragit R.L-100 and Flurbiprofen as a
model drug and studied to determine the mechanism by which surfactant increase the rate of
drug release. It was concluded that for the matrix the major mechanism by which surfactant
increase  drug  dissolution  rates  is  through  the  formation  of  pores  to  aid  the  access  of
dissolution fluid and egress of the dissolved drug.
 Rippe EG,  et  al.49 ,  A stabilized sustained release oral  solid dosage form which
includes  an  effective  amount  of  tramodol  or  pharmaceutically  acceptable  salt  therfof
dispersed in matrix of a hydrophobic material comparising a wax-like substance which was
melted or softened during the preparation of the matrix,is cured at a temperature from about
35 0 C to 65 0 C for a time period from about 4 to about 72 hour , such that the  formulation.
 Skoug J.W. et al. 50 ,The quantities evaluation of the mechanism of release of matrix
sustained release dosage forms by measurement of polymer release.
 
 Hsieh  et  al.51 ,Reported a  more  elegant  version of  this  device which utilized an
inward releasing hemisphere. This hemisphere was coated with an impermeable membrane
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barrier everywhere except a small aperture in the center of this circular face. Such a device
has been applied to polypeptide hormone insulin. 
 Kawasheina  I.  et  al.52 ,A  modified  spherical  agglomeration  technique  as  an
alternative  to  spray  congealing  method.  The  method  of  preparation  will  influence  the
releasing characteristics obtained.
 Chinam  Niranjan  Patra  et  al.53 ,Develop  a  bilayer  tablet  of  propranolol
hydrochloride using superdisintegrant sodium starch glycolate for the fast release layer and
water immiscible polymers such as ethylcellulose, Eudragit RLPO and Eudragit RSPO for
the sustaining layer. The formulations gave an initial burst effect to provide the loading dose
of  the  drug  followed  by sustained  release  for  12  h  from the  sustaining  layer  of  matrix
embedded tablets. In vitro dissolution kinetics followed the Higuchi model via a non-Fickian
diffusion controlled release mechanism after the initial burst release
 Teerawat  Sahasathian  et  al.54 ,  The  Sustained  release  systems  in  the  forms  of
chitosan (CTS) tablet and extrude for releasing amoxicillin. The result showed that chitosan
with the particle size less than 75 µm yielded the best controlled release pattern. Moreover,
the tablets containing chitosan with particle size less than 75 µm were able to provide a
significantly improved sustained release profile of amoxicillin compared to the release profile
of a commercial capsule.
 S.  Prasanna  et.  al.55,  “To  develop  “once  daily”  sustained  release  tablets  of
aceclofenac by direct compression using hydroxypropyl methylcellulose-K4M (HPMC). The
solubility studies of aceclofenac were conducted to select suitable dissolution media.  The
tablets were subjected to physicochemical, in vitro drug release and stability studies”.
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It was observed from the reviewer of literature that very less work has been done on
the formulation of matrix devices of Zidovudine. So, it was proposed to take Zidovudine in
the present study of formulation of matrix tablet. Further it was proposed to use Xanthan,
Ethyl  cellulose,  Hydroxy  propyl  methyl  cellulose  (E.Lv-15),  Carboxy  Methyl  cellulose
Sodium and Eudragit L155 as polymer is very less work has been done on above polymers.
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5.1 DRUG PROFILE56-61  
Figure No.5:- Structure of Trimetazidine HCL
 Drug Name       : Trimetazidine HCL 
Chemical Name: 1-(2, 3, 4-Trimethoxybenzyl) piperazine hydrochloride. (TMZ). 
Molecular Formula: (C14H22N2O3 ) 2HCL
Molecular Weight   : 339.26 g/mol.
Category: Antianginal (vasodilator) Trimetazidine (Di HCl) is used in angina and in 
ischaemia of neuro-sensorial tissues. To prevent the pain of chest due to lack of oxygen to the
muscles of heart.
Solubility: very soluble in water, sparingly soluble in ethanol and practically insoluble in
ether.
 Melting Point:  227°C.
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PHARMACOKINETICS:
PHARMACOKINETIC DATA: 
 Bioavailability-  90%
 Protein binding –16%
 Metabolism - hepatic
 Half life – 6.0 +/- 1.4 hours
 Excretion -  urinary 
 Peak plasma concentration – 84 ng/ml 
 T max – 1.8+/- .7 hrs
 Duration of action – 4 hrs or longer
 Volume of distribution is found to be 4.8 l/kg and plasma protien binding is 16 %. 
PHARMACOLOGY:
Trimetazidine,  known for years to be an effective antianginal  agent,  shifts  cardiac
energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial
long-chain 3-ketoacyl coenzyme A thiolase. By decreasing fatty acid oxidation, trimetazidine
stimulates  glucose  utilization,  restoring  coupling  between  glycolysis  and  carbohydrate
oxidation and leading to adenosine triphosphate production with lesser oxygen consumption.
The  antianginal  properties  of  this  agent  are  devoid  of  haemodynamic  changes,  and
dramatically improve recovery of mechanical function after ischemia.
MECHANISM OF ACTION:
It  has  recently  been  demonstrated  that,  by inhibiting mitochondrial  long-chain  3-
ketoacyl coenzyme A thiolase, trimetazidine alters energy metabolism via inhibitory effects
on  fatty  acid  oxidation,  thus  favouring  glucose  oxidation.  On  the  basis  of  this  recent
observation, trimetazidine is regarded as the prototype of a new class of antianginal agents:
the 3-ketoacyl coenzyme A thiolase inhibitors. The benefits of increased glycolytic substrate
utilization are attributed to a number of mechanisms. The number of moles of adenosine
triphosphatase (ATP) produced per mole of carbon oxidized is approximately 29% higher for
free fatty acids relative to glucose, but the number of moles of ATP produced per mole of
oxygen  consumed is  12% higher  for  glucose than  for  free  fatty acid oxidation.  Thus,  in
normal  conditions,  it  is  more efficient  for  the myocardium to utilize free fatty acids,  but
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during  ischaemia  glucose  is  a  better  substrate.  By  decreasing  fatty  acid  oxidation  and
stimulating  glucose  utilization,  trimetazidine  restores  coupling  between  glycolysis  and
carbohydrate  oxidation,  and  leads  to  ATP production  with  less  oxygen  consumption.  By
stimulating membrane phospholipid turnover during ischaemia and reperfusion, trimetazidine
redirects fatty acids toward phospholipids.
SIDE EFFECTS:
Trimetazidine hydrochloride is safe & well tolerated. In addition, the toxic dose being very 
high, the safety margin of this drug is wide. The most commonly encountered side effects are
gastric discomfort, nausea, headache and vertigo.
INTERACTIONS:
No drug interactions so far have been reported .in particular no interactions have
been reported with beta-blockers, calcium antagonists, nitrates, heparin, hypolipidemic agents
or digitalis praparations.                                                      
5.2 POLYMER PROFILE 62,63
1. HYDROXY PROPYL METHYL CELLULOSE K15CR (HPMC K100M)62
Non-Proprietary Names:
BP            : Hypromellose 
Ph Eur   : Methyl hydroxy propyl cellulosum 
USP          : Hydroxy propyl methyl cellulose 
Synonyms: 
 Cellulose, hydroxypropyl methyl ether, culminal MHPC; E-464, HPMC; Methocel;
methyl  cellulose  propylene  glycol  ether,  methyl  hydroxypropylcellulose,  Metolose,
Pharmacoat. 
Chemical Name: Cellulose, 2-hydroxypropyl methyl ether. 
Empirical Formula & Molecular Weight :
According to European Pharmacopoeia: 
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It is a partly O-methylated & O-(2-hydroxypropylated) cellulose.
Available in several grades with different viscosity and extent of substitution. Grades
may be distinguished by appending a no. indicative of the apparent viscosity, in mpas, of a
2% w/w aqueous solution at 200C. 
According to USP XXII: 
It specifies the substitution type by appending a 4-digit number to a non-proprietary
name, e.g. HPMC1828. First 2 digits refers approximate % of methoxy group (-OCH3) & last
2 digits refers approximate % of hydroxy propoxy group (-OCH2CHOHCH3) calculated on
dried basis. Molecular weight is 10,000-1, 50,000 gm/mol. 
Functional Category:
Coating  agent,  film  former,  stabilizing  agent,  suspending  agent,  tablet  binder,
viscosity – increasing agent.
Application in Pharmaceutical Formulation / Technology: 
 Widely used in oral & topical pharmaceutical formulation. 
 In  oral  product,  HPMC is  generally used as  tablet  binder,  in  film coating & as  an
extended release matrix tablets 2-5% w/w concentration is suitable as binder in either
wet or dry granulation process. 
 High viscosity grades may be used to retard the release of water-soluble drug from
matrix at levels of 10-80%w/w in tablets and capsule.
 Depending on viscosity grade concentration between 2-10% w/w used as film forming
solution to film-coat tablets. Lower viscosity grades are used in aqueous film coating
solution while higher viscosity grades used with organic solvents. 
 Also  used  as  suspending  and  thickening  agent  in  topical  formulation,  mainly  in
ophthalmic preparation, as it forms a clear solution with fewer undispersed fibers as
compared to methylcellulose. So 0.45 –1% w/w used as thickening agent to vehicles for
eye-drops or artificial tear solution. 
 Also used as emulsifier, suspending agent & stability agent in topical gels & ointments.
As  a  protective  colloid  it  can  also  prevent  droplets  &  particles  to  coalescing  or
agglomerating, thus inhibits sediment formation.  
 Also used as adhesive in plastic bandage & wetting agent in topical gels & Ointments.
As  a  protective  colloid  it  can  also  prevent  droplets  and  particles  to  coalescing  or
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agglomerating,  thus  inhibits  sediment  formation.  Also  used  as  adhesive  in  plastic
bandage & wetting agent for hard contact  lenses.  Widely used in cosmetics & food
products.
Description:  Odorless  &  tasteless,  white  or  creamy-white  colored  fibrous  or  granular
powder. 
Solubility: 
In  cold water  forms viscous colloidal  solution, practically insoluble in  chloroform
(CHCl3), ethanol (95%) & water, but soluble in mixture of ethanol & dichloromethane.
Incompatibility:
It is incompatible with some oxidizing agent. As at is nonionic it can’t complex with
metallic salts and ionic organics to form insoluble points. 
Stability & Stability Condition: 
It is a stable material but hygroscopic after drying. Solutions are stable between pH 3-
11. Increase in temperature decreases viscosity of solution, as it undergoes a reversible sol to
gel transformation upon heating and cooling respectively and get point is 50-900C. Aqueous
solutions are enzyme resistant, provide good viscosity during long-term storage, but aqueous
solution liable to microbial  contamination and should be preserved with an antimicrobial
preservative. Stored in a well-closed container, in cool & dry place. 
2. ETHYL CELLULOSE63
Nonproprietary Name: 
BP           : Ethyl Cellulose
Ph Eur    : Ethyl Cellulosum
USP NF   : Ethyl Cellulose.
Synonyms: Aquacoat  ; E462 ; Ethocel ; Surelease.
Chemical Name: Cellulose ethyl ether. 
Empirical  Formula  &  Molecular  Weight:  Ethyl  Cellulose  with  complete  ethoxyl
substitution (DS=3) is C12H23O6 (C12H22O5)n C12H23O5, where “n” can vary to provide a wide
variety of molecular weights.
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Functional  Category:  Coating  agent,  flavoring  agent,  viscosity-increasing  agent,  tablet
binder, tablet filler.
Application in Pharmaceutical Formulations:
 Used as a hydrophobic coating agent for tablets & granules. Ethyl cellulose coatings
are used to modify the release of a drug, to mask unpleasant taste & to improve
stability.
 Used as a matrix former to produce modified release tablets.
 High viscosity grades are used in drug micro-encapsulation.
 Used as a SR tablet coating material in a concentration of 2-3%.
 Used as thickening agent in topical formulations.
Description: It is a tasteless, free flowing, white to light tan-colored powder.
Solubility:  Practically insoluble in glycerin, propylene glycol & water. Ethylcellulose that
contains less than 46.5% ethoxyl group is freely soluble in chloroform, methyl acetate &
tetrahydrofuran, in mixtures of aromatic hydrocarbon with ethanol (95%). Ethylcellulose that
contains not less than 46.5% ethoxyl group is freely soluble in chloroform,ethanol (95%),
ethyl acetate, methanol & toluene
Viscosity: Viscosity increases with an increase in the ethyl cellulose concentration.
Incompatibilities: Incompatible with paraffin wax & microcrystalline wax.
Stability & Storage Conditions:  It shows oxidative degradation in presence of sunlight or
UV light at elevated temperatures, which can be prevented by the use of anti-oxidants &
additives  that  can  absorb  light  at  230-340nm range.  It  should  be  stored  at  a  temp.  not
exceeding 32°C (90°F). It shouldn’t be stored next to peroxides of other oxidizing agents.
3. METALOSE63
Non-Proprietary Name: 
               USP:    Hypermellose
               Substitution Type:         2208
               Viscosity Type    :     100  mPa s
Chemical Name: Cellulose ethyl ether. 
Functional Category: Viscosity-increasing agents, tablet binder, tablet Polymer.
Application in Pharmaceutical Formulations:
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 Used as a hydrophobic coating agent for tablets & granules. Ethyl cellulose coatings
are used to modify the release of a drug, to mask unpleasant taste & to improve
stability.
 Used as a matrix former to produce modified release tablets.
 High viscosity grades are used in drug micro-encapsulation.
 Used as a SR tablet coating material in a concentration of 3-5%.
 Used as thickening agent in topical formulations.
Description:It is a tasteless, free flowing, white to Slightly Off-White Powder.
Viscosity: Viscosity type 100 mPa s.
Spesifications:
Ph             :   5 - 8
Viscosity:   80   -    120
Loss on drying:  5.0 max
Hydroxpropoxy Content:    8.0   -    12.0
Stability  & Storage Conditions:  Storage Conditions:  Store containers  sealed and in dry
place. Keep away from heat or sunlight.
 5.3 EXCIPIENTS PROFILE64
1. STARCH64
Non-Proprietary Name: 
BP               : Maize starch, Potato starch, Wheat starch, Rice starch, Tapioca starch.
Ph Eur         : Maydis amylum, Solani amylum, Tritici amylum, Oryzae amylum.
USP NF      : Corn starch, Potato starch, Wheat starch.
Synonyms:  Amido, amidon, amilo, amylum.
Chemical Name: Starch.
Empirical Formula:  C6H10 O5. 
Molecular Weight: 50,000-160,000.
Functional Category: Glidant and disintegrant; tablet and capsule; tablet binder. 
Application in Pharmaceutical Formulation / Technology: 
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It  is  used as  an excipient  primarily in  oral  solid-dosage formulations  as  a binder,
diluent,  and  disintegrant.  In  tablet  formulations,  freshly prepared  starch  paste  is  used  at
concentration  of  5-25%  w/w  as  a  binder.  Commonly  used  tablet  disintegrants  at
concentrations of 3-15%.  
Description: It  occurs as an odorless and tasteless, fine white-colored powder comprising
very small  spherical  or  ovoid  granules  whose  size  and  shape  are  characteristic  for  each
botanical variety.   
Moisture Content: 18%for potato starch
Swelling temperature: 640C
Solubility: Practically insoluble in cold ethanol (95%) and in cold water.
Stability and Storage Condition:  Stable and stored in air tight container in a cool and dry
place.
2. MAGNESIUM STEARATE64
Non-Proprietary Name: 
BP          : Magnesium Stearate 
Ph Eur    :  Magnesii Stearas
USP NF  : Magnesium stearate 
Synonyms: E572, Hy Qual, Magnesium octadecanoate, stearic acid magnesium salts. 
Chemical Name:  Octadecanoic acid magnesium salt 
Empirical Formula: C36H70mg O4
Molecular Weight:  591.27
Structural Formula: [CH3 (CH2)16 COO]2Mg
Functional Category: It is used as tablet and capsule lubricant. 
Application in Pharmaceutical Formulation / Technology: 
 Used in Cosmetics, foods and pharmaceutical formulations. 
 Primarily used in capsules and tablets manufacturing at a concentration in between
0.25% to 5.0%.
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Description: 
It  is  a  fine,  white,  precipitated or  milled,  impalpable,  greasy powder of low bulk
density, having a faint, characteristics odor and taste. It readily adheres to the skin. 
Moisture: Content: <4%
Solubility: Practically insoluble in ethanol (95%), ether and water. Slightly soluble in warm
benzene and warn ethanol (95%)
Stability and Storage Condition:  Stable and stored in well closed container in a cool and
dry place. 
3. MICROCRYSTALLINE CELLULOSE64
Synonym:  Cellulose gel; crystalline cellulose; Avicel PH 101,102
Empirical Formula: (C6H10O5) n .                                                               
 Molecular weight: Approx. 36000                                                                              
 Description:  Purified,  partially  depolymerised  cellulose  occurs  as  a  white,  odorless,
tasteless, crystalline powder composed of porous particles. Available in different particle size
grades with different properties, i.e., 101 and 102.
 
Density, bulk: 0.28 gm/cm3.
  
                                                 
Density, tapped: 0.43 gm/cm3.                                                                                
 Solubility:  Insoluble in water, dilute acids and most organic solvents.  slightly soluble in
sodium hydroxide solution.                                                                                        
Stability & Storage conditions:Stable, hygroscopic,Store in a well-closed container.
Incompatibilities: None cited in the literature.                               
Handling precautions: No restrictions.                        
Uses: Tablet binder/diluent(5-20%), tablet disintegrant(5-15%), tablet glidant(5-15%), anti-
adherent(5-20%), capsule diluents (10-30%).
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4. TALC64
        It is hydrous magnesium silicate may contain a small amount of aluminum silicate and
iron.
Nonproprietary Name: Purified Talc (BP); Talc (JP); Talc (USP).
Synonym:  Atalc;  hydrous  magnesium  calcium  silicate;  hydrous  magnesium  silicate;
magnesium hydrogen silicate; powdered talc.
Empirical Formula: 
        Mg6 (Si2O5)4 (OH)4
Description:  A very fine, white to grayish-white, impalpable, odorless, crystalline powder.
Adheres readily to skin, soft to touch and free from grittiness.
Typical Properties:
Density, bulk: 19-24 gm/cm3.
Density, tapped: 48-62.5 gm/cm3.
Acidity/Alkalinity: pH= 7-10 for a 20% w/v aqueous dispersion.
Solubility:Insoluble in water, organic solvents, cold acids and dilute alkalis.   
Stability & Storage conditions: Talc is a stable material and may be sterilized by heating at
1600 C for not less than 1 hour. Talc should be stored in a well-closed container in a cool, dry
place.
Incompatibilities: Incompatible with quaternary ammonium compounds.
Handling Precautions: Observe normal precautions appropriate to the circumstances and the
quantity of the material handled. Talc is irritant if inhaled and prolonged excessive exposure 
may cause pneumoconiosis. Eye protection, gloves, and a respirator are recommended.
Table no. 1:-Application in pharmaceutical formulation or technology:
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Use Concentration (%)
Dusting powder (90-99%).
Glidant or tablets lubricant (1-10%)
Diluents for tablets and capsules (5-30%)
Drug and Excipients Profile
5. LACTOSE64: 
It  occurs in  three forms:  -monohydrate,  α-anhydrous,  α-anhydrous. Commercial lactose is
mainly the β-monohydrate.
Chemical name: 4 – 0 -  α-D galactopyranosyl-β-D- glucopyranose.4-(α-D-galactoside)-D-
glucose.
Empirical Formula: Molecular Weight:
C12H22O11 (anhydrous) 342.30
C12H22O11H2O (monohydrate) 360.31
Density (bulk):0.62gm/cm3
Density (tapped):0.94gm/cm3
Description: White to off white or creamy white crystalline particles or powder, odorless;
sweet-tasting.
Solubility: It  is  practically  insoluble  in  chloroform,  ethanol  and  ether  .soluble  in  1in
4.63parts of water
Stability and Storage: Store in a well-closed container to prevent absorption of moisture and
of odors.  Under humid conditions mold growth may occur.  Lactose may develop brown
coloration on storage.  This reaction is accelerated by warm-damp conditions.
Incompatibilities: A mallard  type  condensation  is  likely  to  occur  between  lactose  and
compounds  with  a  primary amino  group  to  form brown  colored  products.  This  reaction
occurs more rapidly with amorphous then crystalline lactose.
Handling precautions: Gloves mask and eye protections are recommended.
Uses: It is used as filler, diluents in pharmaceutical preparation.
6. COLLOIDAL SILICON DIOXIDE64
Synonyme:Aerosil; cab-o-sil ; colloidal silica ; fumed silica ; silica anhydride.
Nonproprietary Name: Colloidal  anhydrous silica (BP),  silica colloidal  is  androecia (Ph
Eur), colloidal silicon anhydrous (USP)
Empirical Formula: SiO2.
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Molecular Weight: 60.08.
Density (bulk): 0.029-0.042g/cm3.
Density (tapped):0.05g/cm3.
Acidity/Alkalinity: pH= 3.5-4.4 (4% aqueous dispersion)
Solubility: Practically insoluble in organic solvent, water and acids; soluble in hot solution of
alkali hydroxide. It forms a colloidal dispersion in water.
Description: It is submicroscopic fumed silica with a particle size of 15nm. It is light, loose,
bluish white colored, odorless, tasteless powder. Several grades of colloidal silicon dioxides
are commercially available.
Functional  Category: Adsorbent;  anticacking  Agent;  emulsion  stabilizer,  glident;
suspending agents; disintegrants; thermal stabilizers; viscosity increasing agents.
Application in Pharmaceutical Formulation or Technology:
Use     Concentration (%)
Aerosols : 0.5-2.0
Emulsion stabilizer : 1.0-5.0
Glidants : 0.1-0.5
Suspending and thickening agents :            2.0-10.0
Stability and Storage Conditions: Aerosil is hygroscopic but adsorb large quantity of water
without liquefying. Viscosity-increasing property is depends on pH.Aerosil powder should be
stored in a well-closed container.
Incompatibilities: Incompatible with diethylstilbestrol preparations. 
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Table No 2: Materials Used
S.No Materials Used Monograph Sources
1. Trimetazidine HCL BP Sharon Bio-Medicine 
LTD.
2. Ethyl Cellulose USP Feicheng Rutai Fine 
Chemicals CO.Ltd.
3. Metalose I.P. Arihant trading Co.Ltd.
4. Hydroxy propyl methyl
cellulose K-15CR
I.P. Shineltsu LTD Japan.
5. Lactose I.P. Berje, Chemical, 
Mumbai
6. M.C.C. I.P. Relience cellulose Pvt. 
Ltd.
7. P.V.P.K.30 I.P. Jyoti Associated Indore
8. Magnesium stearate I.P. Loba Chemie Pvt.Ltd.
9. Talc I.P. J.B. Chemical.
10. Pregelatinised Starch I.P. Loba Chemie Pvt.Ltd.
11. HCL ------- Laboratory.
12. Isoprpyl alcohol ------- Laboratory.
Table No 3: Instruments Used
S.No Types Manufactured by
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1. Digital Weighing Balance Ohaus Corp. Pine Brook, NJ, USA.
2. Hot air oven Unilab, India.
3 Sieve No; # 12, 16,20, 
60,100.
Shreeji, Pharmaceutical, Scientific & 
Laboratory Instruments., India.
4. Compression Machine CIP Machineries Pvt. Ltd., Ahmedabad, 
India.
5. Roche Friabilator Indian Equipment Corporation, Bombay.
6. Monsanto Hardness Tester Rupa Industries, India.
7. Dissolution Test Apparatus Electrolab, Model-TDT-08L, USP.
8. U.V-Spectrophotometer Shimadzu Corporation, Japan.
9. Fourier Transform Infra 
Red Spectroscopy (FTIR)
Nexus-870, Thermo Nicolet, Manisha lab.
10. Distillation Apparatus Borosil, India.
11. Water Bath Unilab, India.
12. Sonicator Spincotech Pvt.Ltd., Italy.
13. pH-meter Elico Ltd. Hyderabad, India.
6.1 Identification of drug (Trimetazidine HCL) sample: 
         It was confirmed by 
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 Melting point 
 FT-IR spectral analysis
 UV absorption maxima
6.1.1. Melting point determination
        Melting point is the temperature at which the pure liquid and solid exist in
equilibrium. In practice, it is taken as equilibrium mixture at an external pressure of 1
atmosphere;  this  is  sometimes known as  normal  melting points.  The  Thiel’s  tube
method of  melting point  determination  in  liquid paraffin  was  used in  the  present
study. Melting point was found to be in the range of 2270C which was in compliance
with the official value.
6.1.2. FTIR Spectra: 
        IR spectra of drug in KBr pellets at moderate scanning speed between 4000-
400 cm-1 was carried out using FTIR (Jasco FTIR 6100 type A). The peak values
(Wave  number)  and  the  possibility  of  functional  group  shown  in  spectra  which
compare with standard value.  The comparison of  these results  with Trimetazidine
HCL chemical structure shows that the sample was pure Trimetazidine HCL.(Figure
No.7).
6.1.3. UV absorption maxima of Trimetazidine HCL:
UV scanning  was  done for  10  mcg/ml  drug solution from 200-400 nm in
phoushphate buffer 6.8 as a blank using double beams UV/VIS spectrophotometer.
The wavelength maximum was found to be at 269 nm (Figure No.11). 
6.2. Characterization of Drug:
6.2.1 Physical description of Trimetazidine HCL: -
Organoleptic properties:
 Trimetazidine HCL is White or almost white crystalline  powder, odorless,  slightly
hygroscopic.
 Solubility: very  soluble  in  water,  sparingly  soluble  in  ethanol  and  practically
insoluble in ether.
Melting point: Its melting point found to be 227oC.
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6.3 Drug Excipients Compatibility study:
        Compatibility of the drug with recipients was determined by FT-IR spectral
analysis, this study was carried out to detect any changes on chemical constitution of
the drug after combined it with the excipients. The samples were taken for FT-IR
study.
6.4 Preparation of buffers:
6.4.1 Preparation of acidic buffers:-
• Preparation of 0.2 M hydrochloric acid:
         HCL diluted with water to contain 7.292 gm of HCl in 1000ml. 
• Preparation of 0.2 M sodium hydroxide solution-
         Dissolve 8.0 g of sodium hydroxide pallets in 1000 ml of distilled water.
6.4.2 Preparation of phosphate buffer: 
• Preparation of 0.2 M potassium dihydrogen phosphate solution-
Dissolve 27.213 g of potassium dihydrogen phosphate in 1000 ml of distilled
water to get 0.2 M potassium dihydrogen phosphate.
• Preparation of 0.2 M sodium hydroxide solution-
         Dissolve 8.0 g of sodium hydroxide pallets in 1000 ml of distilled water.
• Preparation of phosphate buffer pH 6.8 - 
Place 50 ml of 0.2 M potassium dihydrogen phosphate and add 5.6 ml of 0.2
M   of sodium hydroxide. Dilute with distilled water to make up the volume up
to 200ml.
6.5 Preperation of Standard Calibration curve of Trimetazidine HCL-
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Weigh accurately 100mg of Trimetazidine Hcl WS into a 100-ml volumetric
flask;Dissolve  dilute  to  volume  with  phoushphate  buffer  pH.6.8  From  the  stock
solution 10 ml was further  diluted to  100 ml with purified water.  Then from this
solution aliquots of 0.3, 0.6, 0.9, 1.2, 1.5, 1.8, 1.4, 1.6, 1.8 and 2 ml were pipette out
and made up to  10ml with phoushphate  buffer  pH 6.8 The Absorbance  of  above
solution was measured at 269 nm by U.V.Spectrophotometer. 
        The spectrum peak point graph of absorbance of Trimetazidine HCL versus
wave length was shown in Figure No.12.
        
6.6 Evaluation of Powder and Grannuals:
6.6.1 Angle of repose 
Flowability  of  different  batch  of  granules  was  determined  by calculating
angle of repose by fixed height method. A funnel with 10 mm inner diameter of stem
was fixed at a height of 2 cm. over the platform. About 10 gm of sample was slowly
passed along the wall of the funnel till the tip of the pile formed and touches the steam
of the funnel. A rough circle was drawn around the pile base and the radius of the
powder cone was measured. 
Angle of repose was calculated from the average radius using the following 
formula.                                  
                                                       θ = tan− (h/r)
Where, θ = Angle of repose, h = Height of the pile, r = Average radius of the powder
cone.
6.6.2. Bulk density and Tapped density
        An accurately weighed quantity of the powder (W) was carefully poured into the
graduated cylinder and the volume (vo) was measured then the graduated cylinder was
closed with lid, set into the density determination apparatus (bulk density apparatus,
electro lab, Mumbai). The density apparatus was set for 500 taps and after that, the
volume (Vf) was measured and continued operation till the two consecutive readings
were equal. The bulk density, and tapped density were calculated using the following
formulas.
Bulk density = W/Vo
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Tapped density = W/Vf
       Where,    Vo = initial volume
                Vf = final volume.
6.6.3 Compressibility index:
        The Compressibility index and Hausner ratio are measures of the propensity of a
powder to be compressed. As such, they are measures of the relative importance of
interparticulate interactions. In a free-flowing powder, such interactions are generally
less significant, and the bulk and tapped densities will be closer in value. For poorer
flowing materials, there are frequently greater interparticle interactions, and a greater
difference between the bulk and tapped densities will be observed. These differences
are reflected in the Compressibility Index and the Hausner Ratio. 
The  compressibility  index  and  Hausner  ratio  may  be  calculated  using
measured values for bulk density 
 bulk) and tapped density (  tapped) as follows: 
 tapped -  bulk
   Compressibilty Index =       -----------------   X 100
 tapped
                                                 
6.6.4 Hausner Ratio:
It provides an indication of the degree of densification which could result
from vibration of the feed hopper. 
                            Tapped Density
  Hausner Ratio = -----------------------
                            Bulk density
Lower Hausner ratio − Better flowability,
 Higher Hausner ratio − Poor flowability 
6.7 Formulation of Trimetazidine HCL Matrix Tablets:
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Each quantity mentioned will be taken in mgs,
Total weight of the tablet = 180mg
Each tablet contains      = 35mg of the Trimetazidine HCL
Table No.4: Formulation of Trimetazidine HCL Matrix Tablets
Ingrdients F1 F2 F3 F4 F5 F6 F7 F8 F9
Trimetazidine Hcl 35 35 35 35 35 35 35 35 35
Metalose 35 52.5 70 ----- ----- ----- 35 35 35
H.P.M.C.K15CR ----- ----- ----- 35 52.5 70 8.75 17.5 35
Ethyl Cellulose 7 7 7 7 7 7 7 7 7
Pregelatinised
Starch
27 27 27 27 27 27 27 27 27
Microcrystaline
Cellulose
18 18 18 18 18 18 18 18 18
Lactose 44 26.5 9 44 26.5 9 35.25 26.5 9
P.V.P.K.30 7 7 7 7 7 7 7 7 7
I.P.A. q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s.
Aerosil 1 1 1 1 1 1 1 1 1
Talc 3 3 3 3 3 3 3 3 3
Mg.Stearate 3 3 3 3 3 3 3 3 3
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Addition of Binders Solution
                                                                      # 10 Screen
                                                                        
                                                                          Drug in Hot air oven at 60°C                 
                                                                  
                                           
                                                                            # 22 Screen & Adding Lubricant
                                                                        
                                                                                         
                                                                       
                                                     
                                                               
                                                                      
Figure No. 6:-Schematic representation of preparation of Matrix Tablet
6.8. COATING PROCEDURE
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WELL MIXING
COMPRESSION
MATRIX TABLET
DRY GRANULES
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           Weigh accurately H.P.M.C 6 CP and Ethyl Cellulose and mixed in half portion
of I.P.A. Dissolve titaneous oxide, yellow iron oxide, talc in half portion of I.P.A. mix
well half portion of metylene chloride was added in above solution.Dissolve PEG 
6000 in half portion of methylene chloride and added to above solution and stirred 
well.      
Table No. 6:-Coating Formula
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S. No. Ingradients Quantity
1. H.P.M.C. 6 cp 5 mg
2. Etyl Cellulose 0.5 mg
3. Polyethylene Glycol 1 mg
4. Titanium Dioxide 1 mg
5. Yellow Iron Oxide 0.5 mg
6. Talcum 1 mg
7. I.P.A. 0.15 ml
8 Methylene Chloride 0.2 ml
METHODOLOGY
6.9 Evaluation of Tablets:
        All the prepared Sustained release tablets were evaluated for following official
and unofficial parameters.
 Weight Variation
  Thickness
 Hardness Test
 Friability Test
 Drug content
 Dissolution Study
6.9.1. Weight variation:
        Twenty tablets  were  randomly selected  from each  batch and  individually
weighed. The average weight and standard deviation of 20 tablets was calculated. The
batch passes the test for weight variation test if not more than two of the individual
tablet weights deviate from the average weight by more than the percentage shown in
Table no.10 and none deviate by more than twice the percentage shown.
Table No.7:- Percentage deviation allowed under weight variation
Percentage deviation allowed under weight variation test.
Average weight of tablet (X mg) Percentage deviation
X < 80 mg
               
                      80 < X < 250 mg
X > 250 mg
10
7.5
5
6.9.2. Thickness
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        Twenty tablets were randomly selected from each batch and there thickness and
diameter was measured by using digital vernier caliper.
6.9.3 Tablet Hardness
        The crushing strength Kg/cm2 of prepared tablets was determined for 10 tablets
of each batch by using Monsanto tablet hardness tester. The average hardness and
standard deviation was determined. The results are shown in Table No.10
.
6.9.4. Friability:
Method:
       Twenty tablets  were  weighed  and  placed  in  the  Electrolab  friabilator  and
apparatus  was rotated at  25 rpm for  4 minutes.  After revolutions  the tablets  were
dedusted  and  weighed  again.  The  percentage  friability  was  measured  using  the
formula,
% F = {1-(Wt/W)} ×100
Where,  % F = friability in percentage
        W = Initial weight of tablet
       Wt  = weight of tablets after revolution
The results are shown in Table 10.
6.9.5 Assay Procedure: -
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Standard preparation:
Transfer an accurately weighed quantity of about 40 mg of trimetazidine HCL to 200 ml
volumetric flask. Dissolve and dilute to volume with 0.1 N HCL and makeup the volume.
Test preparation:
Crush 20 tablets and weigh accurately 40 mg of powder equivalent to the trimetazidine
HCL into 200 ml volumetric flask. Dissolve and dilute to the volume with 0.1 N HCL
and makeup the volume. Filter the test preparation through 0.45µ filter paper.
Measure the absorbance of standard and test at 269 nm and calculate trimetazidine HCL
by the following equation:
                       Absorbance of sample       wt. of STD       200         avg. wt
% ASSAY=      ----------------------------     x   -------------   x   ------   x   --------- x potency
                       Absorbance of standard          200           test. Wt        L.C.
The results are shown in Table No.10 
6.9.6. In Vitro Dissolution Studies:
        In  Vitro dissolution study was  carried  out using USP I  apparatus  (basket
apparatus)  in 900 ml of  phosphate buffer pH 6.8 for 8 hours. The temperature of the
dissolution medium was kept at 37± 0.5oC and the basket was set at 100 rpm. 10 ml of
sample solution was withdrawn at specified interval of time. The absorbance of the
withdrawn samples was measured at λmax 269 nm using UV visible spectrophotometer.
The concentration was determined from the standard curve  of Trimetazidine HCL
prepared in phosphate buffer pH 6.8 at λ max 269 nm. Cumulative percentage of drug
release was calculated using the equation obtained from a standard curve. 
6.9.7 Swelling Index65
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        The swelling index of tablets was determined in phosphate buffer pH 6.8 at room
temperature.  The swollen weight  of the tablets was determined at  predefined time
intervals. The swelling index was calculated by the following equation:
Swelling index WU =   (W1 – W0)   x 10
                                            W0
                 Where, Wt = Weight of tablet at time t.
                  W0 = Initial weight of tablet
.
6.9.8 Modeling of Dissolution Profiles66  
        In  vitro  dissolution has  been recognized  as an important  element  in  drug
development  under  certain  assessment  of  Bioequivalence.  Several  theories/kinetics
models describe drug dissolution from immediate and modified release dosage forms.
There  are  several  models  to  represent  the  drug  dissolution  profiles  where  ft is  a
function of‘t’ (time) related to the amount of drug dissolved form the pharmaceutical
dosage  system  (Costa  and  Lobo,2001).Whenever  a  new  solid  dosage  form  is
developed or produced, the drug release/dissolution from solid pharmaceutical dosage
form is necessary to ensure that the drug dissolution occurs in an appropriate manner.
          The quantitative interpretation of the value obtained from the dissolution assay
is  facilitated  by  mathematical  equation  which  translates  the  dissolution  curve  in
function of some parameters related with the pharmaceutical dosage forms.  
In  the  present  study,  data  of  the  in  vitro release  were  fitted  to  different
equations and kinetic models to explain the release kinetics of Trimetazidine HCL
from the matrix tablets. The kinetic models used were a Zero order equation, Higuchi
release.
Drug release models:
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To describe the kinetics of the drug release from the matrix tablet batches,
mathematical models such as zero-order, first order, Higuchi, Hixon-crowell models
were used. The criterion for selecting the most appropriate model was chosen on the
basis of the goodness-or fit test. 
The zero-order kinetic describes the systems in which the drug release rate is
independent  of  its  concentration.  The  first  order  kinetic  describes  the  systems  in
which the drug release rate is concentration dependent. Higuchi described the release
of drug from an insoluble matrix as square root of time dependent process. 
In  case  of  the Higuchi  square  root  model  gives  the  drug release  from a
planer  surface  of  an  insoluble  heterogeneous  matrix  by  diffusion  through  the
intragranular openings created by porosity of the matrix tablet. 
6.10 Stability Studies67
 Selected formulations were subjected to stability studies as per I.C.H. 
Guidelines.
Following conditions were used for stability studies
 30°C/65 % RH analyzed till a period of 30 days
 40°C/75 % RH analyzed till a period of 30 days
Following parameters  were check for stability studies
Hardness, friability, drug content and in vitro release.
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RESULTS AND DISCUSSION
7.1 IDENTIFICATION OF DRUG:-
7.1.1 FTIR Spectra: 
        IR spectra of drug in KBr pellets at moderate scanning speed between 4000-
400 cm-1 was carried out using FTIR (Jasco FTIR 6100 type A).  The peak values
(Wave  number)  and  the  possibility  of  functional  group  shown  in  spectra  which
compare with standard value. 
  The comparison of these results with trimetazidine HCL chemical structure
shows that the sample was pure Trimetazidine HCL. Figure No.7.
7.1.2 UV absorption maxima of Trimetazidine HCL:
   UV scanning was done for 10 mcg/ml drug solution from 200-400 nm in 0.1
N HCL as a blank using double beams UV/VIS spectrophotometer.   The wavelength
maximum was found to be at 269 nm (Figure No. 11). 
7.2 Drug Excipients Compatibility study:
                Compatibility of the drug with recipients was determined by FT-IR spectral
analysis, this study was carried out to detect any changes on chemical constitution of
the drug after combined it with the excipients.
                The samples were taken for FT-IR study. (Figure No. - 8, 9, 10).
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Figure No. 7:- IR Spectrum of Pure Drug (Trimetazidine HCL)
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7.2.1 Drug Excipients Compatibility study:
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Figure No.10:-IR Spectrum of Drug + Ethyl cellulose
  
  IR spectra studies revealed that the drug and polymers used were compatible.
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7.3 Determination of λ max:
Figure No.11:-Absorbance Maxima of Trimetazidine HCL
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7.4 Calibration Curve of Trimetazidine HCL
Table No. 7:- Calibration curve of Trimetazidine HCL
Figure No. 12:- Calibration Curve of Trimetazidine HCL
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Concentrarion Absorbance at
269nm
0 0
3 0.049
6 0.105
9 0.162
12 0.217
15 0.266
18 0.321
21 0.386
24 0.433
27 0.495
30 0.587
                                                              Results and Discussion
7.5 Evaluation of Powders:-
7.5.1 Preformulation Studies:-
Table No.8:- Preformulation studies of pure drug and polymers
Parameter
Results
Trimetazidine 
HCL
HPMC-K-15
CR
Metalose Etyl Cellulose
Angle of Repose 24 22 19 26
Bulk Density
(gm/cm3)
0.46 0.31 0.35 0.60
Tapped Density
(gm/cm3)
0.72 0.52 0.59 0.77
Compressibility
Index
36.11 40.34 40.67 22.07
Hauser’s Ratio 1.56 1.60 1.68 1.28
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Table No. 9:- Preformulation studies of blend
BATCH
NO.
BULK
DENSITY
(g/ml)
TAPPED
DENSITY
(g/ml)
COMPRSI
BILITY
(%)
HOUSNER
RATIO
ANGLE OF
REPOSE
(°)
F1 0.314 0.389 19.2 1.237624 250
F2 0.368 0.426 13.6 1.157407 180
F3 0.399 0.476 16.2 1.193317 200
F4 0.354 0.416 17.51 0.86 29011’
F5 0.399 0.476 16.2 1.193317 20o12’
F6 0.421 0.512 17.7 1.215067 230
F7 0.458 0.534 14.3 1.166861 200
F8 0.316 0.409 29.43 0.77 31016’
F9 0.366 0.457 24.86 0.80 240
            Preformulation study was done initially and results directed for the further
course  of  formulation.  Based  on  Preformulation  studies  different  batches  of
Trimetazidine HCL (F1 to F9) were prepared using selected excipients.
 Powders  were  evaluated  for  tests  Angle  of  repose,  Bulk  density,  tapped
density, compressibility index, Hausner ratio before being punched as tablets. 
7.5.2 Physico-Chemical Evaluation of Matrix Tablets:
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       The results of the thickness, Hardness, weight variation, drug content, friability,
disintegration time of tablet are shown in Table No.10.
Table No. 10:- Results of Thickness, weight variation, Hardness, Friability and
Drug content
BATC
H NO.
WEIGHT
VARIATIO
N 
FRIABILIT
Y
(%)
HARDNES
S
(kg/cm2)
THICKNES
S
(mm)
DRUG
CONTENT
(%)
F1 ±4.0 0.12 4.5 3.9 96.20
F2 ±2.0 0.19 5 4 97.26
F3 ±3.0 0.39 5 4.1 98.93
F4 ±2.55 0.14 5 4 97
F5 ±2.0 0.24 5 3.9 99.89
F6 ±3.44 0.11 5.5 3.8 98.53
F7 ±2.0 0.43 4 4.1 97.11
F8 ±5.66 0.16 5 3.9 97
F9 ±5.22 0.18 5.5 3.8 96.00
 7.5.3 In Vitro Dissolution Studies
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            Table No.11 shows the data for in vitro release of Trimetazidine HCL from
matrix tablet of batches F1, F2, F3, F4, F5, F6, F7, F8 and F9 respectively.
           As follows the dissolution profiles shows the comparative release profile of
Trimetazidine HCL with different concentration  of  different polymer from batches
F1, F2, F3, F4, F5, F6, F7, F8, F9 of matrix tablet. 
Table No. 11:- Cumulative % Release of Drug of various Formulations
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Time(Hr) F1 F2 F3 F4 F5 F6 F7 F8 F9
0 0 0 0 0 0 0 0 0 0
1 40.5 41.1 42.31 38.25 45.04 36.83 33.78 37.47 34.61
2 54.44 59.07 58.14 48.75 54.14 51.01 45.73 55.06 50.36
4 80.51 84.25 81.38 81.18 78.1 73.38 67.16 77.81 68.95
6 88.23 90.08 89.99 89.99 85.31 84.43 72.93 85.52 72.98
8 91.19 92.86 92.95 92.95 86.84 89.96 85.02 87.75 80.77
                                                              Results and Discussion
Figure No.13:- Graph of the Cum. % drug release versus Time (hrs)
7.5.4. % Swelling Index of Tablets of Batch F1 toF9
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Batch TIME (HRS)0 1 2 3 4 5 6
F1 0 32.23 41.38 54.32 63.78 74.12 81.2
F2 0 49.25 61.54 72.90 82.37 92.54 100.22
F3 0 29.09 39.45 51.32 61.12 71.97 80.35
F4 0 39.21 51.92 63.76 72.52 84.2 96.56
F5 0 45.65 53.35 64.32 75.45 80.09 94.58
F6 0 56.73 66.76 77.72 82.26 94.60 101.25
F7 0 39.06 47.96 55.32 65.34 76.09 87.11
F8 0 25.87 36.54 47.86 57.98 69.96 72.44
F9 0 26.76 40.98 49.54 59.06 69.78 75.99
Table No.12:- % Swelling Index of Tablets of Batch F1 toF9
Figure No. 14:- Comparison of % swelling index of various formulations
7.5.5 Kinetic assessment of Extended release Matrix tablet containing 
Trimetazidine HCL-
Huguchi Modeling -
Dept. Of Pharmaceutics, PGPCPS&RI 83
                                                              Results and Discussion
Table No. 13:- Huguchi Modeling 
                                                                                    
BATCHES R2 VALUE
(ZERO ORDER)
R2 VALUE
      (HUGUCHI)
F1 0.809 0.971
F2 0.787 0.961
F3 o.798 0.969
F4 0.802 0.975
F5 0.768 0.955
F6 0.851 0.988
F7 0.865 0.991
F8 0.802 0.968
F9 0.807 0.973
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Figure No. 15:- Huguchi Modeling
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              Figure No. 16:- Zero order Modeling
7.6 Stability Study of Optimized Formulation: - 
      As per I.C.H. Guidelines
Table No. 14: Stability studies of formulation F-9 stored at 30°C/65 % RH
Time (hr) Cumulative % Drug Release
Initial After 30 Days
0 0 0
1 34.61 34.01
2 50.36 50.98
4 68.95 67.33
6 72.98 71.61
8 80.77 80.11
Hardness 5.5 5.5
Friability 0.18 0.17
Drug
content 96 95.92
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Table No- 15:- Stability 
studies of formulation 
F-9 stored at 40°C/75 %
RH
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Time (hr) Cumulative % Drug Release
Initial After 30 Days
0 0 0
1 34.61 33.53
2 50.36 50.12
4 68.95 66.65
6 72.98 72.53
8 80.77 79.78
Hardness 5.5 5.5
Friability 0.18 0.18
Drug
content 96 94.99
                                                                Summary and Conclusion
SUMMARY AND CONCLUSION
           Oral  route  of  drug  administration  is  oldest  and  safest  mode  of  drug
administration.  It  posses  several  advantages.  It  provides  accurate  dosing  without
assistantship of administration. In conventional oral drug delivery system, there is little or
no control  over  release  of  drug,  and  effective  concentration at  the  target  site  can  be
achieved  by  administration  of  grossly  excessive  dosage  form. Sustained  release
technology is relatively new field and as a consequence, research in the field has been
extremely fertile and has produced many discoveries. With many drugs, the basic goal is
to achieve a steady state blood level that is therapeutically effective and non-toxic for an
extended period of time. The design of proper dosage form is an important element to
accomplish this goal.
        Trimetazidine HCL is Vasodilator with half life of 6 hours and requires
multiple  daily doses  to  maintain  adequate  plasma concentrations.  So it  is  selected  to
prepare  an  extended  release  Matrix  tablet.  The  objective  of  this  present  study  is  to
develop an extended release Matrix tablet of Trimetazidine HCL which releases the drug
in an extended manner over a period of 8 hours, by using different polymers and study on
polymer concentration effect on release pattern.
        The present study was undertaken with an aim to formulate develop and evaluate
Trimetazidine HCL extended release matrix tablets using different polymers as release
retarding agent.
        Preformulation study was done initially and results directed for the further course of
formulation.  Based on Preformulation studies different  batches  of Trimetazidine HCL
were  prepared  using  selected  excipients.  Powders  were  evaluated  for  tests  Angle  of
repose,  Bulk density,  tapped  density,  compressibility index, and Hausner  ratio  before
being punched as tablets. 
         IR spectra studies revealed that the drug and polymers used were compatible.
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        Various formulations of sustained release matrix tablets of Trimetazidine HCL were
developed using various polymers viz, HPMC K-15CR, Hypermellose, Ethyl Cellulose in
different proportions and combinations by Wet Granulation technique. The tablets were
evaluated for physical characterization,  in vitro swelling behavior,  in vitro release study
and stability studies.
        Observations of all formulations for physical characterization had shown that, all of
them  comply  with  the  specifications  of  official  pharmacopoeias  and/or  standard
references.
        Results of  in vitro release profile indicated that formulation F9 was the most
promising formulation as the extent of drug release from this formulation was high as
compared  to  other  formulations.  Results  of  in-vitro  swelling  study  indicate  that  the
formulation F9 was having considerable swelling index.
        Stability study was  conducted  on tablets  of  Batch  F9  stored  at  300C (Room
Temperature) and 400C for one month. Tablets were evaluated for hardness, friability, in-
vitro  release  profile  and  drug  content.  After  one  month  no  significant  changes  were
observed  in  any  of  the  studied  parameters  during  the  study period,  thus  it  could  be
concluded that formulation was stable. It was concluded that the tablets of batch F9 had
considerable swelling behaviors and in vitro drug release. Percentage drug release in 8 hr
is 80.77.  It was observed that tablets of batch F9 followed the Huguchi release profiles. 
        From the above results and discussion it is concluded that formulation of Extended
release  matrix  tablet  of  Trimetazidine  HCL  containing  HPMC  K-15  (19.44%)  and
Hypermellose (19.44%), Ethyl cellulose (19.44%) batch F9 can be taken as an ideal or
optimized formulation Extended release matrix tablet for 8 hour release as it fulfills the
requirements for extended release matrix tablet. 
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